



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

**FORM 1 -- NOTICE OF A PUBLIC HEARING OR COMMENT PERIOD ON A PROPOSED RULE
(Page 1)**

AGENCY Health And Human Resources

RULE TYPE Legislative AMENDMENT TO EXISTING RULE No TITLE-SERIES 69-12

RULE NAME Medication - Assisted Treatment - Office - Based Medication Assisted Treatment

CITE AUTHORITY §16-5Y-1

**COMMENTS LIMITED TO
Written**

DATE OF PUBLIC HEARING

LOCATION OF PUBLIC HEARING

**DATE WRITTEN COMMENT PERIOD ENDS
Sunday, August 07, 2016 4:00 PM**

**WRITTEN COMMENTS MAY BE MAILED TO
M. Katherine Lawson, Inspector General
WV DHHR, Office of the Inspector General
State Capitol Complex
Building 6, Room 817-B
Charleston, WV 25305**

BY CHOOSING 'YES', I ATTEST THAT THE PREVIOUS STATEMENTS ARE TRUE AND CORRECT.

**Yes
Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in
accordance with West Virginia Code §29A-3-11 and §39A-3-2.**



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

**FORM 1 -- NOTICE OF A PUBLIC HEARING OR COMMENT PERIOD ON A PROPOSED RULE
(Page 2)**

AGENCY **Health And Human Resources**

RULE TYPE **Legislative** AMENDMENT TO EXISTING RULE No TITLE-SERIES **69-12**

RULE NAME **Medication - Assisted Treatment - Office - Based Medication Assisted Treatment**

CITE AUTHORITY **§16-5Y-1**

PROVIDE A BRIEF SUMMARY OF YOUR PROPOSAL

This rule applies to any publicly or privately owned medication-assisted treatment program in physicians offices that treat individuals with substance use disorders through the prescription, administration or dispensing of medication-assisted treatment medication in the form of opioid agonist, partial opioid agonist or other medication-assisted treatment medication as defined in W. Va. Code § 16-5Y-2 and further described in this rule.

BY CHOOSING 'YES', I ATTEST THAT THE PREVIOUS STATEMENTS ARE TRUE AND CORRECT.

Yes

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 11 -- FISCAL NOTE FOR PROPOSED RULES (Page 1)

AGENCY Health And Human Resources

RULE TYPE Legislative AMENDMENT TO EXISTING RULE No TITLE-SERIES 69-12

RULE NAME Medication - Assisted Treatment - Office - Based Medication Assisted Treatment

CITE AUTHORITY §16-5Y-1

PRIMARY CONTACT

M. Katherine Lawson, Inspector General
WV DHHR, Office of the Inspector General
State Capitol Complex, Building 6, Room S17-B
Charleston, STATE ZIP

SECONDARY CONTACT

Melanie A. Pagliaro
WV DHHR, Office of the Cabinet Secretary
One Davis Square, Suite 100, East
Charleston, STATE SECONDARY ZIP SECONDARY

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 11 -- FISCAL NOTE FOR PROPOSED RULES (Page 1)

AGENCY Health And Human Resources

RULE TYPE Legislative AMENDMENT TO EXISTING RULE No TITLE-SERIES 69-12

RULE NAME Medication - Assisted Treatment - Office - Based Medication Assisted Treatment

CITE AUTHORITY §16-5Y-1

SUMMARIZE IN A CLEAR AND CONCISE MANNER WHAT IMPACT THIS MEASURE WILL HAVE ON COSTS AND REVENUES OF STATE GOVERNMENT.

The estimated cost of this rule is \$0 in FY 2017 as the costs will be absorbed in the first year. Office of Health Facility Licensure and Certification (OHFLAC) currently licenses and regulates nine opioid treatment programs through the existing regulatory structure and will be able to use existing resources initially to begin the operation of the program. Depending upon the number of clinics and providers ultimately subject to regulation, the Department expects to spend approximately \$256,576 in subsequent years.

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 11 -- FISCAL NOTE FOR PROPOSED RULES (Page 2)

AGENCY **Health And Human Resources**
RULE TYPE **Legislative** AMENDMENT TO EXISTING RULE No TITLE-SERIES **69-12**
RULE NAME **Medication - Assisted Treatment - Office - Based Medication Assisted Treatment**

CITE AUTHORITY **§16-5Y-1**

FISCAL NOTE DETAIL -- SHOW OVER-ALL EFFECT IN ITEM 1 AND 2 AND, IN ITEM 3, GIVE AN EXPLANATION OF BREAKDOWN BY FISCAL YEAR, INCLUDING LONG-RANGE EFFECT.

Effect Of Proposal	Current Increase/Decrease (use ' - ')	Next Increase/Decrease (use ' - ')	Fiscal Year (Upon Full Implementation)
ESTIMATED TOTAL COST	0.00	0.00	256,576.00
PERSONAL SERVICES			170,820.00
CURRENT EXPENSES			85,756.00
REPAIRS AND ALTERATIONS			
ASSETS			
OTHER			
ESTIMATED TOTAL REVENUES	0.00	17,100.00	60,000.00

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 11 -- FISCAL NOTE FOR PROPOSED RULES (Page 3)

AGENCY **Health And Human Resources**

RULE TYPE **Legislative** AMENDMENT TO EXISTING RULE No **TITLE-SERIES 69-12**

RULE NAME **Medication - Assisted Treatment - Office - Based Medication Assisted Treatment**

CITE AUTHORITY **§16-5Y-1**

3. EXPLANATION OF ABOVE ESTIMATES (INCLUDING LONG-RANGE EFFECT). PLEASE INCLUDE ANY INCREASE OR DECREASE IN FEES IN YOUR ESTIMATED TOTAL REVENUES.

The proposed rule will regulate office based medication-assisted treatment programs throughout the state. Currently, OHFLAC regulates only opioid treatment programs and uses surveyors in its behavioral health program to perform annual surveys of licensed entities. It is anticipated that in year one, FY 2017, OHFLAC will absorb the costs of the program as its existing surveyors transition from opioid treatment program regulation to medication-assisted treatment regulation.

In subsequent years, beginning in FY 2018 as the program expands, it is anticipated that OHFLKAC will need an additional 4 Surveyors FTEs (average salary and benefits is \$42,705). Total personal service costs for OHFLAC is estimated at \$170,820 upon full program implementation. Current expenses to accommodate OHFLAC travel, training and office supplies is estimated at \$55,972 per year (\$13,993 x 4 FTEs). Rent and utilities for the new OHFLAC staff is estimated at \$9,004 per year (\$2,251 x 4 FTEs). There is a one time cost of \$6,580 for the purchase of computer equipment (\$1,645 x 4 FTEs. To accommodate the additional staff members, OHFLAC will need to purchase two additional vehicles at a cost of \$14,200 (includes vehicle cost, maintenance and gas).

The anticipated revenues from license fees is estimated at \$17,100 for FY 2016 and \$60,000 for FY 2017. These figures are based upon an estimate to 100 offices performing office-based medication assisted treatment in FY 2017. It is unknown how many licenses may fall under the new regulation, but it is anticipated that additional revenues will be collected in subsequent years.

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 11 -- FISCAL NOTE FOR PROPOSED RULES (Page 4)

AGENCY **Health And Human Resources**

RULE TYPE **Legislative** AMENDMENT TO EXISTING RULE No **TITLE-SERIES 69-12**

RULE NAME **Medication - Assisted Treatment - Office - Based Medication Assisted Treatment**

CITE AUTHORITY **§16-5Y-1**

PLEASE IDENTIFY ANY AREAS OF VAGUENESS, TECHNICAL DEFECTS, REASONS THE PROPOSED RULE WOULD NOT HAVE A FISCAL IMPACT, AND OR ANY SPECIAL ISSUES NOT CAPTURED ELSEWHERE ON THIS FORM.

SBS 454 created a regulatory program for medication assisted treatment programs. For rulemaking purposes, it was determined that two rules were necessary to implement the program. A separate fiscal note has been created for Medication Assisted Treatment - Opioid Treatment Program.

BY CHOOSING 'YES', I ATTEST THAT THE PREVIOUS STATEMENTS ARE TRUE AND CORRECT.

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708



**WEST VIRGINIA
SECRETARY OF STATE**

NATALIE E. TENNANT

ADMINISTRATIVE LAW DIVISION

eFILED

7/8/2016 2:35:43 PM

OFFICE OF
WEST VIRGINIA SECRETARY OF STATE

FORM 12 -- BRIEF SUMMARY AND STATEMENT OF CIRCUMSTANCES (Page 1)

AGENCY **Health And Human Resources**

RULE TYPE **Legislative** AMENDMENT TO EXISTING RULE No TITLE-SERIES **69-12**

RULE NAME **Medication - Assisted Treatment - Office - Based Medication Assisted Treatment**

CITE AUTHORITY **§16-5Y-1**

SUMMARIZE IN A CLEAR AND CONCISE MANNER CONTENTS OF CHANGES IN RULE AND STATEMENT OF CIRCUMSTANCES REQUIRING THE RULE.

Through the passage of SB 454 during the 2016 Regular Session of the West Virginia Legislature, the Secretary of the Department of Health and Human Resources is mandated to promulgate legislative rules establishing specific standards and procedures to provide for the licensure or registration and regulation of two types of medication-assisted treatment programs, including office-based medication-assisted treatment programs. The other type of medication-assisted treatment program authorized by SB 454 will be addressed in a separate rule, 69 CSR 11.

BY CHOOSING 'YES', I ATTEST THAT THE PREVIOUS STATEMENTS ARE TRUE AND CORRECT.

Yes

Melanie A Pagliaro -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.



Title-Series: 69-12



Rule Id: 10220



Document: 27708

TITLE 69
LEGISLATIVE RULE
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

SERIES 12
MEDICATION-ASSISTED TREATMENT – OFFICE-BASED MEDICATION-ASSISTED TREATMENT

§69-12-1. General.

1.1. Scope. -- This legislative rule establishes standards and procedures for the licensure and regulation of medication-assisted treatment – office-based medication-assisted treatment (OBMAT) programs.

1.2. Authority. -- W. Va. Code §§16-5Y-1, et seq.

1.3. Filing Date. --

1.4. Effective Date. --

1.5. Purpose. -- The purpose of this rule is to ensure that all West Virginia OBMAT programs conform to a common set of minimum standards and procedures to ensure the care, treatment, health, safety and welfare of patients therein.

1.6. Enforcement. -- This rule is enforced by the Secretary of the Department of Health and Human Resources or his or her designee.

§69-12-2. Definitions.

2.1. Definitions incorporated by reference. -- Those terms defined in W. Va. Code §§16-5Y-1, et seq. are incorporated herein by reference.

2.2. Administrative Detoxification or Administrative Withdrawal --The detoxification from the approved medication-assisted treatment medication for the safety and well-being of the patient, other patients and staff of the OBMAT program.

2.3. Advanced Practice Registered Nurse -- A registered nurse who has acquired advanced clinical knowledge and skills preparing him or her to provide direct and indirect care to patients, completed a board approved graduate-level education program, passed a board-approved national certification examination, and has met all the requirements set forth by the West Virginia Registered Nurses Board.

2.4. Adverse Event or Incident -- An event involving an immediate threat to the care or safety of an individual, either staff or patient; the possibility of serious operational or personnel problems within the OBMAT program facility; or the potential to undermine public confidence in the OBMAT program.

2.5. Approved Authorities -- Programs or authorities that publish practice or treatment guidelines, standards or protocols that the secretary has approved for use by OBMAT programs. Approved authorities include the American Society of Addiction Medicine (ASAM); the Center for Substance Abuse

Treatment (CSAT); the National Institute on Drug Abuse (NIDA); the American Association for the Treatment of Opioid Dependence (AATOD); the Federation of State Medical Boards; and any other program or authority approved by the secretary.

2.6. Case Management -- The process of coordinating and monitoring the services provided to a patient both within the program and in conjunction with other providers.

2.7. Clinical Staff -- The individuals employed by or associated with a program who provide treatment, care or rehabilitation to program patients or patients' families.

2.8. Co-Occurring Disorders -- The combination of current or former substance use disorders and any other mental disorders recognized in the current edition of the *Diagnostic and Statistical Manual of Mental Disorders* published by the American Psychiatric Association.

2.9. Counseling Session -- A face-to-face interaction in a private location between a patient(s) and a primary counselor for a period of no less than 30 minutes designated to address patient substance use disorder issues or coping strategies and individualized treatment plan of care.

2.10. Counselor -- A person who, by education, training and experience, is qualified to provide psychosocial education, treatment and guidance to patients enrolled with an OBMAT program and, if desired, to the families of such patients, in order to accomplish behavioral health, wellness, education and other life goals.

2.11. Crisis -- A deteriorating or unstable situation often developing suddenly or rapidly that produces acute, heightened, emotional, mental, physical, medical or behavioral distress; or any situation or circumstance in which the individual perceives or experiences a sudden loss of his ability to use effective problem-solving and coping skills.

2.12. Critical Incident -- A life, safety or health threat involving the staff or patients participating in a program, including, but not limited to, death or physical or sexual assault.

2.13. Detoxification or Medically Supervised Withdrawal Treatment -- The dispensing of a medication-assisted treatment medication to a patient in decreasing doses over time, under the supervision of a program physician, to alleviate adverse physical or psychosocial effects incident to withdrawal from the continuous or substantial use of an opioid drug.

2.14. Discharge Plan -- The written plan that establishes the criteria for a patient's discharge from a service and identifies and coordinates delivery of any services needed after discharge.

2.15. Dispense -- The preparation and delivery of a medication-assisted treatment medication in an appropriately labeled and suitable container to a patient by an OBMAT program, but does not include the preparation and delivery of medications by a pharmacy licensed pursuant to the provisions of W.Va. Code §§ 30-5-1, *et seq.*

2.16. Diversion -- An activity involving the legitimate acquisition of pharmaceutical agents illegally diverted to entities not intended as the recipients by the initial supplier.

2.17. Diversion Control Plan -- A required plan developed and implemented by the OBMAT program, which may include, but is not limited to, the assigning of responsibilities to medical and administrative

staff and other specific measures to reduce the possibility of diversion of controlled substances from legitimate treatment to illicit use.

2.18. For-Cause Inspection -- An inspection by any federal or state agency or accreditation body of an OBMAT program that may be operating in violation of federal or state medication-assisted treatment standards, may be providing substandard treatment or may be serving as a possible source of diverted medications.

2.19. Grievance -- A written or oral complaint filed by a patient with a program administrator, medical director or state agency alleging inadequate treatment by the OBMAT program.

2.20. Individualized Treatment Plan of Care or Treatment Plan -- A plan or strategy of treatment and care developed by the patient's physician, counselors and other health care professionals in conjunction with the patient that outlines attainable short-term treatment goals that are mutually acceptable to the patient and the OBMAT program and which specifies the services to be provided and the frequency and schedule for their provision.

2.21. Induction -- Initial treatment of a patient with medication-assisted treatment medication in order to suppress signs or symptoms of withdrawal or substance cravings; and generally includes a gradual increase in medication-assisted treatment medication therapy until the symptoms are regularly and reliably suppressed or controlled.

2.22. Initial Assessment -- An assessment conducted prior to or at admission and initial screening of a proposed patient that focuses on the individual's eligibility or need for admission and treatment; and provides indicators for initial dosage level and forms the basis for the individualized treatment plan of care.

2.23. Inspection or Survey -- Any examination by the secretary or his or her designee of an OBMAT program including, but not limited to, the premises, staff, patients and documents pertinent to initial and continued registration, so that the secretary or his or her designee may determine whether a program is operating in compliance with registration requirements or has violated any registration requirements. This includes any survey, monitoring visit, complaint investigation or other inquiry conducted for the purposes of making a compliance determination with respect to registration requirements.

2.24. Long-Term Detoxification Treatment -- Detoxification or medically supervised withdrawal treatment for a period of more than 30 days.

2.25. Maintenance Dose -- The level of medication-assisted treatment medication considered medically necessary to consistently suppress signs or symptoms of substance use disorders and substance cravings for individuals with a substance use disorder; and is generally administered at the end of the induction period and is individualized for each patient and may gradually change over time.

2.26. Medical and Rehabilitative Services -- Treatment and recovery services such as medical evaluations, counseling and rehabilitative and other social programs intended to help patients in OBMAT programs become and remain productive members of society.

2.27. Medical or Patient Record -- Medical histories, records, reports, summaries, diagnoses, prognoses, records of treatment and medication ordered and given, entries, x-rays, radiology

interpretations and other written electronic, or graphic data prepared, kept, made or maintained in a facility that pertains to services rendered to patients.

2.28. Medical Withdrawal -- The medically managed, gradual, voluntary and therapeutic withdrawal of a patient from medication-assisted treatment, agreed upon by the patient and staff.

2.29. Medication Administration -- The direct application of medications by injection, inhalation, ingestion or any other means to a patient receiving services by persons legally permitted to administer medication-assisted treatment medications or the individual at the direction and in the presence of persons legally permitted to administer medication-assisted treatment medications.

2.30. Medication Error -- An error in administering a medication to an individual and includes when any of the following occur: the wrong medication is given to an individual; the wrong individual is given the medication; the wrong dosage is given to an individual; medication is given to an individual at the wrong time or not at all; or the wrong method is used to administer the medication.

2.31. Mental Health Professional -- A person licensed under chapter 30 of the West Virginia Code as a social worker, psychologist or professional counselor.

2.32. Misuse or Non-Medical Use -- All uses of a prescription medication or substance other than those that are directed by a physician and used by an intended patient within the law and the requirements of good medical practice.

2.33. Opioid Drug -- Any substance or drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug or substance having such addiction-forming or addiction-sustaining liability including, but not limited to, heroin, morphine, codeine, Oxycontin, oxycodone and other medications that block the transmission of pain messages to the brain.

2.34. Opioid Treatment Services -- Treatment and services provided by an OBMAT program that uses medication-assisted treatment medications as a part of its treatment modality. Opioid treatment services may be provided through intensive outpatient, residential or hospital settings; and may include medical maintenance, medically supervised withdrawal and detoxification, various levels of medical, psychosocial and other types of care, detoxification treatment, and maintenance treatment.

2.35. Peer Recovery Support Services -- Non-clinical recovery support services which are recipient directed and delivered by peers who have life experience with recovery.

2.36. Pharmacotherapy -- The treatment of disease or medical condition through the administration of drugs.

2.37. Physical Dependence -- A state of biologic adaption that is evidenced by a class-specific withdrawal syndrome when the substance is abruptly discontinued or the dose rapidly reduced, or by the administration of an antagonist.

2.38. Physician Extender -- A medical staff person other than a program physician, functioning within his or her scope of practice to provide medical services to patients admitted to OBMAT programs. Physician extenders approved for employment at an OBMAT program include advance practice registered nurses or physician assistants. Registered nurses and licensed practical nurses are not

authorized to act as physician extenders in an OBMAT program, although they may work within the program in other capacities.

2.39. Plan of Correction -- A written description of the actions the OBMAT program intends to take to correct and prevent the reoccurrence of violations of a statute, rule, regulation or policy identified by the designated state oversight agency during an investigation or survey.

2.40. Plan of Education -- An approved continuing education plan that results in a physician, counselor or physician extender attaining professional competence in the field of substance use disorder treatment.

2.41. Positive Drug Screen -- A test that results in the presence of any drug or substance listed in section 33.2.e. of this rule or any other drug or substance prohibited by the OBMAT program. The presence of medication which is part of the patient's individualized treatment plan of care shall not be considered a positive test. Any refusal to participate in a random drug test shall be considered a positive drug test.

2.42. Primary Counselor -- The individual designated by the OBMAT program to serve as a consultant and advisor to a patient on a regular basis. The primary counselor may be an addiction counselor and shall be included as a member of the patient's interdisciplinary team for opioid treatment programs.

2.43. Program Physician --- Any physician designated and approved by the medical director to prescribe and monitor medication-assisted treatment for patients admitted to an OBMAT program. The medical director may serve as a program physician.

2.44. Random Drug Testing -- Approved medical screening and testing of patients for drugs, alcohol or other substances that shall be conducted so each patient of an OBMAT program has a statistically equal chance of being selected for testing at random, unscheduled times.

2.45. Recovery --- A process of change through which an individual improves his or her health and wellness, lives a self-directed life and strives to achieve his or her full potential.

2.46. Relapse Prevention Plan -- A plan of action developed by a patient and his or her primary counselor to help the patient anticipate and prepare for situations or environmental stimuli that were previously associated with substance abuse or addiction in order to avoid a return to use of opioids or other inappropriate or addictive substances.

2.47. Titration -- The gradual increasing or decreasing of doses of a medication-assisted treatment medication to the minimal level clinically required for maintenance.

§69-12-3. State Opioid Treatment Authority.

3.1. The secretary has designated the Bureau of Behavioral Health and Health Facilities as the state opioid treatment authority.

§69-12-4. State Oversight Authority; Powers and Duties.

4.1. The secretary has designated the Office of Health Facility Licensure and Certification (OHFLAC) within the Department of Health and Human Resources to act as the state oversight agency, as that

agency is defined in this rule. OHFLAC shall provide regulatory oversight, regulation and inspection of OBMAT programs.

4.2. The powers and duties of the state oversight agency include, but are not limited to, the following:

4.2.a. Develop and implement rule and regulations regarding the registration and oversight of OBMAT programs;

4.2.b. Accept applications and fees for registration of OBMAT programs and conduct all necessary reviews, inspections or investigations in order to determine whether a registration should be issued;

4.2.c. Issue initial, amended and renewed registration to an OBMAT program upon a determination that the program is qualified;

4.2.d. Perform both scheduled and unscheduled site visits to OBMAT programs when necessary and appropriate;

4.2.e. Monitor the activities of all OBMAT programs to ensure compliance with all state and federal requirements;

4.2.f. Receive and act upon complaints;

4.2.g. Inspect allegations of rule or regulation violations, unauthorized activities or other conduct that may affect the health, safety or well-being of patients or employees of an OBMAT program;

4.2.h. Assist an OBMAT program in developing a plan of correction in order to correct any noted violations or deficiencies;

4.2.i. Deny, revoke or suspend the registration of an OBMAT program in accordance with the applicable administrative proceedings; and

4.2.j. Perform all other necessary actions related to the registration, monitoring, investigating and oversight of OBMAT programs.

§69-12-5. Certification; Approval and Exemptions.

5.1. Hospitals that are licensed under "Hospital Licensure," 64 C.S.R § 12, and behavioral health facilities that are licensed under "Behavioral Health Centers Licensure," 64 C.S.R. § 11, and which provide medication-assisted treatment as defined in W. Va. Code § 16-5Y-2 are subject to the provisions of this rule and to all other relevant federal and state licensing requirements as specified by the secretary.

5.2. An OBMAT program directly operated by the Department of Veterans Affairs, the Indian Health Service or any other department or agency of the United States is not required to obtain a state license.

5.3. Crisis Stabilization Units (CSU) are not required to obtain a state license if the following conditions are met:

5.3.a. Treatment at the CSU is for no more than 7 days; and

5.3.b. The CSU must document the referral of the patient to an appropriate MAT program upon discharge from the CSU.

§69-12-6 Registration for OBMAT programs; Fees and Costs.

6.1. General Registration Provisions.

6.1.a. No person, partnership, association or corporation may operate an OBMAT program in the state of West Virginia without first obtaining a registration pursuant to W. Va. Code § 16-5Y-4.

6.1.b. A registration is valid only for the location and persons named and described in the application.

6.1.c. Each OBMAT program location shall be registered separately, regardless of whether the program is operated under the same business name or management as another program.

6.1.d. Before establishing, operating, maintaining or advertising an OBMAT program within the state of West Virginia, a program shall:

6.1.d.1. If the OBMAT program dispenses MAT medications, they must be registered and qualified by the United States Department of Health and Human Services under the Controlled Substances Act to dispense medication-assisted treatment medications in the treatment of substance use disorder; and

6.1.d.2. Obtain from the secretary a registration authorizing the operation of the OBMAT program and facility.

6.1.e. Each registered OBMAT program shall designate a medical director unique to that program. The medical director shall practice at the program and be responsible for the operation of the program in accordance with the requirements of this rule. Nothing within this rule will prevent an OBMAT program from designating two co-medical directors.

6.1.f. A license or registration is not transferable or assignable.

6.1.g. If the ownership of an OBMAT program changes, the new owner shall notify the secretary within 10 days and immediately apply for a new registration. The new owner's application for a registration is valid for three months from the date the application is received by the director.

6.1.h. The OBMAT program shall notify the secretary in writing 30 days prior to a change in name or location of the program and request an application form for a registration amendment.

6.1.i. If there is a change in the medical director, the OBMAT program must comply with the provisions of section 7.3.f. of this rule.

6.1.j. If the OBMAT program is not in substantial compliance with this rule, but does not pose a significant risk to the health, safety or rights of the patients, a registration expiring in less than one year may be issued.

6.1.k. The secretary or his or her designee may enter the premises of any practice, office or facility if the secretary has reasonable belief that it is being operated or maintained as an OBMAT program without a registration.

6.1.l. If the owner, medical director or other person in charge of a licensed or registered OBMAT program or of any other unregistered practice, office or facility which the secretary has reasonable belief is being operated as an OBMAT program refuses entry pursuant to this rule, the secretary shall petition the Circuit Court of Kanawha County or the county in which the program is located for an inspection warrant.

6.1.m. If the secretary finds on the basis of an inspection that any person, partnership, association or corporation is operating as an OBMAT program without a registration, the OBMAT program shall apply for a license within 10 days.

6.1.n. An OBMAT program that fails to apply for a registration is subject to the penalties established by section 30 of this rule.

6.1.o. An OBMAT program shall surrender an expired, revoked or otherwise invalid registration to the secretary upon written demand.

6.2. Registration Application.

6.2.a. The owner(s) of an OBMAT program shall submit an application for an OBMAT program registration to the secretary not less than 30 days and not more than 60 days prior to the anticipated initiation of services.

6.2.b. All applications for an initial, provisional or renewed registration shall include and provide the documentation specified in W. Va. Code § 16-5Y-4 in addition to the following:

6.2.b.1. Documentation of all current federal accreditations, certifications and authorizations; and

6.2.b.2. A description of the organizational structure of the OBMAT program.

6.3. Registration Fees and Inspection Costs.

6.3.a. All applicants for an initial, provisional or renewed registration shall be accompanied by a non-refundable fee in the amount required by this rule. The annual renewal fee is based upon the average daily total census of the program. In addition to the set fee, the annual renewal fee shall be adjusted on the first day of June of each year to correspond with increases in the consumer price index. The base amounts for initial, provisional and renewal fees are as follows:

6.3.a.1. Initial registration fee – \$250;

6.3.a.2. Provisional registration fee – only for existing programs as of the effective date of this rule seeking an initial license – \$250; and

6.3.a.3. Renewal registration fee – \$500 plus adjustment.

6.3.b. An OBMAT program shall pay for the cost of the initial inspection made by the secretary prior to issuance of a registration. The cost of the initial inspection of an OBMAT program is \$250 plus the cost of the inspection and shall be billed to the applicant by the secretary.

6.4. Initial Inspection and Issuance of Registration.

6.4.a. Upon receipt of an application for an initial registration to operate as an OBMAT program, the secretary or his or her designee shall make an inspection of the program and facility in order to determine whether the program has satisfied all of the federal and state requirements for registration.

6.4.b. If the inspection reveals violations, deficiencies or shortcomings on the part of the OBMAT program or facility, the secretary shall advise the program of the deficiencies. The program may submit one or more written plans of correction demonstrating compliance with the corrections required. The secretary may conduct follow-up inspections if required.

6.4.c. Following an application review, onsite inspection or inspections and approval of subsequent plans of correction as may be needed, if there is substantial compliance with the requirements of this rule and the cost of the inspection has been paid as required by section 6.3, the secretary shall issue a license or registration in one of three categories:

6.4.c.1. An initial registration, valid for 12 months from the date of issuance, shall be issued to programs establishing a new service found to be in substantial compliance on initial review with regard to policy, procedure, facility and recordkeeping regulations;

6.4.c.2. A provisional registration shall be issued when an OBMAT program seeks a renewal, or is an existing program as of the effective date of this rule and is seeking an initial registration, and the OBMAT program is not in substantial compliance with this rule, but does not pose a significant risk to the rights, health and safety of a consumer. It shall expire not more than six months from the date of issuance, and may not be consecutively reissued; or

6.4.c.3. A renewal registration shall be issued when an OBMAT program is in substantial compliance with this rule. A renewal registration shall expire not more than 12 months from the date of issuance.

6.4.d. A registration is valid for the OBMAT program named in the application and is not transferrable or assignable.

6.5. Denial of Registration.

6.5.a. The secretary may deny an application for an initial, provisional or renewal registration if:

6.5.a.1. The secretary determines that the application is deficient in any respect;

6.5.a.2. The OBMAT program will not be or is not being operated in accordance with federal or state treatment standards, or federal or state standards, laws and rules;

6.5.a.3. The OBMAT program will not permit an inspection or survey to proceed or will not permit in a timely manner access to records or information deemed relevant by the secretary;

6.5.a.4. The OBMAT program has made misrepresentations in obtaining accreditation, certification, licensure or registration;

6.5.a.5. The OBMAT program fails to have a medical director practicing at the program location; or

6.5.a.6. The OBMAT program fails to have an established process for maintaining current, accessible patient records from admission through discharge.

6.5.b. If the secretary determines not to issue a registration, the secretary shall notify the applicant in writing of the denial and the basis for the decision. Following the denial, the program must follow closure procedures in sections 35 and 36.2. of this rule, including notification to existing patients.

6.5.c. An OBMAT program shall surrender an expired, revoked or otherwise invalid registration to the secretary upon written demand.

6.5.d. An OBMAT program may protest the denial of an initial, provisional or renewal registration pursuant to the administrative procedures in section 36.2 of this rule.

6.6. Renewed or Amended Registrations.

6.6.a. The OBMAT program shall submit an application for a renewed registration to the secretary not less than 60 days prior to the expiration of the current registration. After the secretary receives a complete renewal application with the required fee, the existing registration shall not expire until the new registration has been issued or denied.

6.6.b. The program shall notify the secretary 30 days prior to a change in the name, geographic location or services of a program or a change in the substantial nature of the OBMAT program and simultaneously shall apply for a registration amendment.

§69-12-7. Administrative Organization and Management of OBMAT Programs.

7.1. Each OBMAT program shall identify a program administrator, medical director, program physician(s), and counseling staff.

7.2. Program Administrator.

7.2.a. The administrator of an OBMAT program shall have at a minimum a bachelor's degree in an appropriate area of study and a minimum of four years of experience in the fields of substance use disorders, behavioral health or health care administration or a master's degree in an appropriate professional area of study and a minimum of two years of experience in the fields of substance use disorders, behavioral health or health care administration; or eight years of experience in the fields of substance use disorders, behavioral health or health care administration.

7.2.b. The administrator is responsible for the day-to-day operation of the OBMAT program in a manner consistent with the laws and regulations of the United States Department of Health and Human Services, Drug Enforcement Administration (DEA), and the laws and rules of the state of West Virginia.

7.2.c. Duties of the administrator include:

7.2.c.1. Contributing to development of policies and procedures for operation of the program;

7.2.c.2. Maintenance and security of the facility;

7.2.c.3. Employment, credentialing, evaluation, scheduling, training and management of staff;

7.2.c.4. Protection of patient rights;

7.2.c.5. Conformity of the program with federal confidentiality regulations, namely, 42 C.F.R. Part 2;

7.2.c.6. Security of medication storage and safe handling of medications;

7.2.c.7. Contributing to the management of the facility budget;

7.2.c.8. Implementation of program policies and procedures and governing body policy; and

7.2.c.9. Communication with the medical director and governing body.

7.3. Medical Director.

7.3.a. Each OBMAT program shall have a designated medical director. The medical director shall have a full, active and unencumbered license to practice allopathic medicine or surgery from the West Virginia Board of Medicine or to practice osteopathic medicine or surgery from the West Virginia Board of Osteopathic Medicine in this state.

7.3.b. The medical director shall also meet the following requirements:

7.3.b.1. If the medical director prescribes a partial opioid agonist, he or she shall complete the requirements for the Drug Addiction Treatment Act of 2000; and

7.3.b.2. Demonstrate experience in substance use disorder treatment and medication-assisted treatment; or

7.3.b.3. Have a written plan to attain competence in substance use disorder treatment and medication-assisted treatment within a probationary time period as provided in section 7.3.c. herein.

7.3.c. The medical director may submit a written plan to attain competence in substance use disorder treatment and medication-assisted treatment to the state opioid treatment authority and state oversight authority for approval at least two weeks prior to employment at an opioid treatment program.

7.3.c.1. The time frame for completion of the plan may not exceed 12 months from the date of the appointment as medical director. The physician may work as a medical director during this probationary time period, subject to the supervision and reporting requirements of this rule.

7.3.c.2. During the probationary time period, the medical director shall be supervised on a regular basis by a physician licensed in this state with demonstrated competence in the field of substance use disorder and medication-assisted treatment.

7.3.c.3. Consultation with and supervision of a medical director during the probationary time period may be provided by telephone or video conferencing and shall be documented, initialed or verified, either in ink or electronically, and dated by both the supervising and supervised physicians.

7.3.c.4. The administrator of the OBMAT program is responsible for maintaining documentation regarding the medical director's training and experience in a file which is current and readily available at all times. The administrator also is responsible for ensuring that the plan of development is completed within the approved time lines.

7.3.c.5. The state opioid treatment authority may request periodic documentation of continuing education during the initial probationary period and afterward if the documentation provided at the end of that period is not satisfactory.

7.3.d. The medical director shall maintain authority over the medical aspects of treatment offered by the OBMAT program. The medical director is responsible for:

7.3.d.1. Operation of all medical aspects of the treatment program;

7.3.d.2. Administration and supervision of all medical services;

7.3.d.3. Ensuring that the OBMAT program is in compliance with all applicable federal, state and local laws, rules and regulations;

7.3.d.4. Obtaining and maintaining his or her continuing medical education in the field of substance use disorder treatment and medication-assisted treatment on a documented and ongoing basis;

7.3.d.5. Approving the basic and continuing educational programs of all staff employed by or volunteering at the OBMAT program; and

7.3.d.6. Determining the ability of the program physicians and physician extenders to work independently within the applicable scope of practice.

7.3.e. The medical director shall practice 75 percent of the hours in which the OBMAT program is operating each week in order to ensure regulatory compliance and carry out those duties specifically assigned to the medical director. Nothing in this rule prohibits an OBMAT from designating co-medical directors.

7.3.f. Within 10 days after the withdrawal or termination of the medical director, the owner or owners of the program shall notify the secretary of the identity of another medical director for the program. During the interim, not to exceed 60 days, another licensed physician shall be present during all hours of operation and shall assume the duties of the medical director on a temporary basis until such time as a new medical director is identified and begins work at the program. The interim physician may be another owner of the program or a program physician employed by or associated with the program.

7.4. Professional Medical Staff.

7.4.a. The OBMAT program may employ and use program physicians, physician extenders and other health care professionals working within their scope of practice who have received sufficient education, training, experience, or any combination thereof, to enable that person to perform the assigned functions. All physicians, nurses and other licensed professional care providers must comply with the credentialing requirements of their respective professions. The OBMAT program may only employ registered nurses, advance practice registered nurses and physician's assistants as physician extenders.

7.4.b. All physicians and physician extenders employed by the OBMAT program shall be actively licensed in West Virginia and shall have:

7.4.b.1. A minimum of one year's experience in substance use disorder treatment and medication-assisted treatment settings; or

7.4.b.2 Meet the following requirements:

7.4.b.2.A. Active enrollment in a plan of education for obtaining competence in medication-assisted treatment methods and substance use disorders that is approved by the medical director. The medical director shall certify the individual's completion of the plan of education when, in the discretion of the medical director, it is satisfactorily accomplished; and

7.4.b.2.B. Complete the certification, training programs or continuing education programs recommended and approved by the medical director of the OBMAT program.

7.4.c. During all hours of operation, every OBMAT program shall have an actively licensed program physician on call and available for consultation with other staff members at any time.

7.4.d. During all hours of operation, every OBMAT program shall have present and on duty at the program at least one of the following actively-licensed health care professionals:

7.4.d.1. Physician

7.4.d.2. Physician assistant;

7.4.d.3. Advanced practice registered nurse; or

7.4.d.4. Registered nurse.

7.4.e. Plans of Education.

7.4.e.1. Program physicians and physician extenders operating under a plan of education shall be supervised by the medical director at a frequency appropriate for the qualifications and experience of the employee.

7.4.e.2. The program administrator of the OBMAT program or their designee shall document when an employee undertakes a plan of education; maintain all records regarding plans of education for the professional medical staff; and ensure that the medical director monitors and certifies satisfactory completion of each plan of education.

7.4.e.3. The medical director shall approve each plan of education and the ability of a program physician or physician extender to work independently within his or her scope of practice. The medical director shall sign an affidavit that verifies and documents an employee's successful completion of a plan of education and the medical director's approval for that person to provide services on an independent basis within his or her scope of practice.

7.5. Counseling Staff.

7.5.a. Counseling through an OBMAT program shall be provided by counseling staff that meet the qualifications as described W.Va. Code § 16-5Y-5(d).

7.5.b. The OBMAT program shall assign a primary counselor to each patient to contribute to the appropriate treatment plan for the patient and to monitor patient progress.

7.5.c. Each OBMAT program's policies and procedures shall establish ratios of primary counselors to persons served that are adequate to allow sessions to occur as mandated and that will allow persons served access to a primary counselor, either on site or by referral, but there shall be at least one counselor for every 50 patients in the program.

7.5.d. Any unlicensed or uncertified counseling staff employed or used on a referral basis by the program shall be directly supervised by a licensed or certified professional or advanced alcohol and drug counselor, or both. At a minimum, the supervisor shall provide at least one hour of supervision per 20 hours of direct service. Supervision may be group in nature, but must consist of case consultation and discussion or clinical training rather than administrative oversight.

7.5.e. The administrator of the OBMAT program is responsible for documentation of supervision, which shall be available for review at all times.

7.5.f. Newly employed counselors and other non-physician clinical staff without experience in a recovery-based OBMAT program shall receive initial training lasting at least 20 hours and consisting of, at a minimum, the following:

7.5.f.1. Substance use disorder overview;

7.5.f.2. Opioid treatment, detoxification protocols, recovery models and basic pharmacology and dosing;

7.5.f.3. Characteristics of the substance use disorder population;

7.5.f.4. Toxicology screening and observation of sample collection;

7.5.f.5. Program policy and procedure;

7.5.f.6. Confrontation, de-escalation and anger management;

7.5.f.7. Cultural sensitivity as necessary and appropriate;

7.5.f.8. Current strategies for identifying and treating alcohol, cocaine and other substance use disorders;

7.5.f.9. Identification of co-occurring behavioral health or developmental disorders; and

7.5.f.10. Other clinical issues as appropriate for the population served.

7.5.g. An experienced counselor newly employed from another MAT program may be exempt from the mandatory initial training required by this rule, if the program is able to verify and document that mandatory initial training has been received within the previous two years. The administrator of the OBMAT program shall document in the personnel file any exemption granted and the basis for the exemption.

7.5.h. Counselors with less than one year of full-time experience in the field of substance use disorder treatment and medication-assisted treatment shall accompany an experienced counselor at all times for a minimum of two weeks before seeing persons served without immediate and constant supervision.

7.6. Unlicensed Clinical Staff and Volunteers.

7.6.a. An OBMAT program may employ unlicensed clinical staff and utilize volunteers to assist in the operation of the program and facility. The program shall develop and implement policies and procedures which specify the roles and responsibilities of each unlicensed employee and volunteer. Documentation of the responsibilities, training and other obligations of an unlicensed clinical staff employee or volunteer shall be included in the personnel file of the employee or volunteer.

7.6.b. All unlicensed clinical staff and volunteers shall receive direct on-site supervision and be provided with assistance, directions for activity and support.

§69-12-8. Environment and Operation of Office-Based Opioid Treatment Programs.

8.1. Service Operation Schedule.

8.1.a. Programs, especially sole practitioners or OBMAT programs, shall ensure that services are not interrupted due to staff vacations by having qualified, temporary coverage.

8.1.b. Except as otherwise provided herein, the program's days of operation shall meet the needs of the OBMAT program patients served.

8.1.c. The program shall develop and implement the following for days not in operation, if applicable:

8.1.c.1. The program shall notify the individuals receiving medication-assisted treatment services in writing at least 30 days in advance of their intent to close on Sunday or permanently change service hours. All individuals shall receive an orientation addressing policies and procedures, and this orientation shall be documented in the individual's record prior to receiving mediations; and

8.1.c.2. The program shall establish procedures for emergency access to dosing information 24 hours a day, seven days a week. This information may be provide via an answering service or other electronic measure. Information needed includes the patient's last dosing time and date, and dose.

8.2. Payments for services rendered may be made either by West Virginia Medicaid, private insurance, or by cash as described in 8.2.d.

8.2.a. The OBMAT program shall be eligible for, and not prohibited from, enrollment with West Virginia Medicaid and other private insurance.

8.2.b. Prior to directly billing a patient for any opioid treatment, the OBMAT program must receive either a rejection of prior authorization, or rejection of a submitted claim or a written denial from a patient's insurer or West Virginia Medicaid denying coverage for such treatment.

8.2.c. The OBMAT program shall document in the patient's record any rejection of prior authorization, rejection of a submitted claim for written denial from a patient's insurer or West Virginia Medicaid denying coverage for opioid treatment. The OBMAT program shall also clearly document in the patient's record if the patient has no insurance or has voluntarily and with full knowledge of the financial obligations, including all treatment costs, requested a claim not be submitted to their insurer or West Virginia Medicaid. When any instance described in this section regarding direct billing and acceptance of cash payments from a patient occurs, the OBMAT program shall clearly document in the patient's record the rationale and medical necessity for acceptance into the program.

8.2.d. The OBMAT program may directly bill and accept cash payments from a patient only after the requirements of sections 8.2.a., 8.2.b. and 8.2.c. herein, have been fulfilled and documented.

8.2.e. At the option of the OBMAT program, treatment may commence prior to billing.

8.3 Each OBMAT program facility shall have:

8.3.a. Sufficient space and adequate equipment for the provision of all services specified in the program's description of treatment services;

8.3.b. Clean, safe and well-maintained patient and staff areas;

8.3.c. A secure room and lockable equipment for patient records;

8.3.d. Private offices or areas for individual and group therapeutic meetings, sufficient in number to address the counseling and treatment needs of the population served;

8.3.e. Sanitary, secure and private dosing areas, if applicable;

8.3.f. Sufficient restrooms for the estimated patient population with areas for observation of specimen production, if necessary; and

8.3.g. Adequate parking areas for the expected flow of traffic.

8.4. The OBMAT program facility may provide security personnel in lobby and parking areas, either clinic staff or contracted, if the population served or clinic environment warrants such an arrangement. If contracted staff is used for security, the staff must be trained in patient confidentiality.

8.5. Infection Control.

8.5.a. The OBMAT program shall develop, implement and maintain an effective infection control program that protects the patients, their families and clinic personnel by preventing and controlling infections and communicable diseases.

8.5.b. The program shall include the implementation of a nationally recognized system of infection control guidelines.

8.5.c. The OBMAT program shall have an active surveillance and education program for the prevention, early detection, control and investigation of infections and communicable diseases.

8.5.d. The OBMAT program shall designate a person or persons, with appropriate education and training, as infection control officer to develop and implement policies governing control of infections and communicable diseases for patients and personnel.

8.6. Community Relations.

8.6.a. The program shall develop and implement policies and procedures for community relations to include the following:

8.6.a.1. A program shall be responsible for ensuring that its patients do not cause unnecessary disruption to the community or act in a manner that would constitute disorderly conduct or harassment by loitering on the program's property;

8.6.a.2. Each program shall provide the state opioid treatment authority and state oversight authority, when requested, with a specific plan describing the efforts it will make to avoid disruption of the community by its patients and the actions it will take to assure responsiveness to community needs. This plan shall, at a minimum:

8.6.a.2.A. Identify program personnel who will function as community relations coordinators and define the goals and procedures of the community relations plan;

8.6.a.2.B. Include policies and procedures to resolve community problems, including, but not limited to, patient loitering and medication diversion, to ensure that program operations do not affect community life adversely; and

8.6.a.2.C. Include policies and procedures for soliciting patient and community ideas about medication-assisted treatment, addressing community concerns and the program's presence in the community.

8.6.a.3. Each program shall document community relations efforts and community contacts, including the resolution of issues identified by community members or patients.

8.7. Emergency Preparedness. -- The program's emergency preparedness plan shall include, but not be limited to, the provision of the continuation of medication-assisted treatment in the event of an emergency or natural disaster.

§69-12-9. Facility Construction and Renovations; Life Safety Policies and Procedures

9.1. Before extensive construction or renovation of an OBMAT program facility begins, the program shall submit to the secretary for approval a complete set of the plans for the project, which includes the drawings and specifications for the architectural, structural and mechanical design and work.

9.2. The secretary shall advise the program whether approval has been granted. In the event the plans for the project are not approved, the secretary shall set forth in writing the reasons for the disapproval and provide the program the opportunity to correct any deficiencies. Extensive construction or renovation of a facility may not begin until the secretary has issued final approval of the plans.

9.3. All OBMAT program facilities shall comply with the current standards of the Americans with Disabilities Act of 1990, as amended.

9.4. All OBMAT program facilities must meet all other requirements of applicable federal or state regulatory or oversight agencies.

9.5. Life Safety Policies and Procedures.

9.5.a. Each OBMAT program shall develop, implement and maintain policies and procedures regarding the appropriate and safe administration of medications and other medical treatment. The policies and procedures shall:

9.5.a.1. Ensure that the correct dose of medication is administered and that appropriate actions are taken if a mistake is made, including a mechanism for reporting unusual incidents to appropriate program staff;

9.5.a.2. Establish a current plan of emergency administration of medications in case the program must be closed temporarily, including how patients will be informed of these emergency arrangements;

9.5.a.3. Ensure that there is appropriately trained staff on duty at all times who are proficient in cardiopulmonary resuscitation and reversal of opiate overdose; and

9.5.a.4. Ensure that each medication-assisted treatment medication used by the OBMAT program is administered and dispensed, if applicable, in accordance with its approved product labeling. Dosing, dispensing and administration decisions shall be made by a program physician familiar with the most up-to-date product labeling. These procedures must ensure that any significant deviations from the approved labeling, including deviations with regard to dose frequency, or the conditions of use described in the approved labeling, are specifically documented in the patient's record.

9.6. Each OBMAT program shall develop, implement and maintain policies and procedures regarding safe and effective access to the facility and staff. The policies and procedures shall:

9.6.a. Provide 24 hour, seven day-per-week access to designated program staff, as described in section 8.1.c.2., so that patient emergencies may be immediately addressed and dosage levels verified;

9.6.b. Require the program to display in facility offices and waiting areas the names and telephone numbers of individuals or agencies who should be contacted in case of an emergency;

9.6.c. Include an up-to-date disaster plan that specifies emergency evacuation procedures, fire drills and maintenance of fire extinguishers; and

9.6.d. Address safety and security issues for patients and staff, including training staff to handle physical or verbal threats, acts of violence, inappropriate behavior, or other escalating and potentially dangerous situations, with emphasis on when security guards or police need to be summoned.

§69-12-10. For-Cause Inspections; Complaints.

10.1. The secretary may at any time conduct unannounced inspections of an OBMAT program for cause if the secretary has received a complaint about the program or has reason to believe that the program may be operating in violation of federal or state statutes, rules or regulations, may be providing substandard treatment or may be serving as a possible source of diverted medications.

10.2. Any person may file a complaint with the secretary alleging violation of applicable laws, rules or policies by an OBMAT program. A complaint shall identify the OBMAT program by name and state the nature of the complaint.

10.3. At the time of any on-site investigation activities, the investigator shall notify the medical director or program administrator at OBMAT program of the general reason for the investigation.

10.4. Within 15 working days of the investigation, the secretary shall provide to medical director or program administrator at an OBMAT programs a written report of the results of the investigation. The report shall specify any deficiency found and the rule that forms the basis for the violation.

10.5. The secretary may permit the OBMAT program to develop a plan of correction to address any noted violations or deficiencies. The secretary may advise and consult with the medication director, program administrator or other personnel at an OBMAT programs with the OBMAT program in order to assist with a plan of correction.

10.6. The secretary may impose a civil money penalty, suspend or revoke a license or take such other action as deemed appropriate to address any violations or deficiencies. In the event the secretary determines that the continued operation of the OBMAT program is a threat to the health, welfare and safety of its patients or employees, the secretary may issue an order immediately closing the facility pursuant to applicable administrative procedures.

10.7. Upon completion of the investigation, the secretary shall notify the complainant whether the allegations have been substantiated and how to obtain a copy of the report.

10.8. The secretary shall keep confidential any information that could reasonably lead to the identification of a complainant and of any patient involved in the complaint or investigation. The secretary shall not disclose such information without the written consent of the complainant or patient. The secretary shall delete any identifying information before disclosure of investigative information to the public.

10.9. If a complaint becomes the subject of a judicial proceeding, nothing in this rule prohibits the disclosure of information that would otherwise be disclosed in judicial proceedings.

10.10. The secretary may suspend or revoke a license of an OBMAT program for violating the prohibitions of this rule.

§69-12-11. Plans of Correction.

11.1. Within 10 working days after receipt of the inspection report, the program administrator or medical director at an OBMAT program shall submit to the secretary for approval a written plan to correct all deficiencies that are in violation of this rule, unless a waiver or variance is requested by the OBMAT program and granted by the secretary. The plan of correction shall specify:

11.1.a. Any action taken or procedures proposed to correct the deficiencies and prevent their reoccurrence;

11.1.b. The date of completion or each action taken or to be taken; and

11.1.c. The signature of the head of the governing body or his or her designee.

11.2. The proposed plan of correction shall be approved, modified or rejected by the secretary in writing. The OBMAT program may make modifications to the plan at a later date in conjunction with the secretary.

11.3. The secretary shall state the reasons for rejection or modification of any plan of correction.

11.4. The program administrator or medical director at an OBMAT program shall submit a revised plan of correction to the secretary within 10 working days of receipt of a rejection by the secretary.

11.5. The OBMAT program shall immediately correct a violation that severely risks the health or safety of a patient or other persons.

11.6. The secretary shall determine if satisfactory corrections have been made and advise the program medical director at an OBMAT program of any compliance or continued deficiencies in writing.

11.7. The secretary may provide consultation to the applicant or licensee in obtaining compliance with this rule.

§69-12-12. Waivers and Variances.

12.1. The secretary may grant a waiver or variance to the provisions of this rule under any of the following circumstances:

12.1.a. A strict application of the rule clearly would be impractical and if any alternate arrangements are not detrimental to the health or safety of the patients or employees of the program;
or

12.1.b. A waiver, variance or extension of a provisional license is necessary under extraordinary circumstances or otherwise to protect public health; or

12.1.c. The waiver or variance serves the best interests of patient safety and quality of care.

12.2. Any waiver or variance approved by the secretary shall be in writing.

12.3. All waivers or variances shall be reviewed at least annually by the designated state oversight agency.

§69-12-13. Reports and Records.

13.1. Inspection Reports and Records.

13.1.a. The secretary shall keep on file a report of any inspection, survey or investigation of an OBMAT program or any program sponsor, owner, employee, volunteer or patient thereof.

13.1.b. Information in reports or records shall be available to the public except for the following:

13.1.b.1. Information regarding complaints and subsequent investigations that is deemed confidential by any provision of this rule or applicable state or federal laws;

13.1.b.2. Information of a personal nature from a patient or personnel file; or

13.1.b.3. Information required to be kept confidential by state or federal law.

13.1.c. A report of an inspection or investigation made public shall also state whether a plan of correction has been submitted to or approved by the secretary.

13.2. Statistical Reports and Records.

13.2.a. The OBMAT program shall file a quarterly statistical report with the secretary on a form prescribed by the secretary, which includes the following information:

13.2.a.1. The total number of patients receiving medication-assisted treatment;

13.2.a.2. The number of patients who have been continually receiving medication-assisted treatment in excess of two years, including the total number of months of treatment for each of these patients;

13.2.a.3. The state of residency of each patient;

13.2.a.4. The number of patients discharged from the program;

13.2.a.5. The total months the patients were in the treatment program prior to discharge;

13.2.a.6. Whether the discharge was for:

13.2.a.6.A. Termination or disqualification;

13.2.a.6.B. Voluntary withdrawal prior to completion of all requirements of detoxification as determined by the OBMAT program;

13.2.a.6.C. Successful completion of the individualized treatment plan of care; or

13.2.a.6.D. An unexplained reason;

13.2.a.7. Statistics demonstrating program compliance with the random drug testing requirements of section 33.6 of this rule;

13.2.a.8. Confirmation that the random drug tests were truly random in regard to both the patients tested and to the times random drug tests were administered by lottery or some other objective standard so as not to prejudice or protect any particular patient;

13.2.a.9. Confirmation that the random drug tests were performed in accordance with the requirements in section 33.2.f.

13.2.a.10. The total number tested and the number of positive results; and

13.2.a.11. The number of expulsions from the OBMAT program.

13.3. Incident Reporting and Adverse Events.

13.3.a. Each OBMAT program shall develop and implement policies and procedures for comprehensively documenting, investigating, taking corrective action and tracking instances of adverse events or incidents.

13.3.b. Adverse events or incidents are defined as an event which may involve:

13.3.b.1. Immediate threat to the care or safety of an individual, whether staff member, visitor, patient or other patient;

13.3.b.2. The possibility of serious operational or personnel problems; or

13.3.b.3. The potential to undermine public confidence in the OBMAT program.

13.3.c. Incidents or adverse events may include:

13.3.c.1. Program medication errors or other known medication errors;

13.3.c.2. Potentially lethal patient suicide attempts;

13.3.c.3. Drug or substance-related hospitalization of a patient;

13.3.c.4. Patient death or serious injury due to trauma, suicide, medication error or unusual circumstances;

13.3.c.5. Harm to family members or others from ingesting a patient's medication;

13.3.c.6. Selling drugs or substances on the premises;

13.3.c.7. Medication diversion;

13.3.c.8. Harassment or abuse, including physical, verbal, sexual and emotional, of patients by staff;

13.3.c.9. Theft, burglary, break-in or similar incident at the program;

13.3.c.10. Violence;

13.3.c.11. Significant disruption of services due to disaster such as fire, storm, flood or other occurrence; and

13.3.c.12. Incident with potential for negative community reaction or which the program director or medical director believes may lead to community concern.

13.3.d. Incidents or adverse events shall be reviewed on a quarterly basis by the medical director at an OBMAT program which may choose to make recommendations to the administration, governing body or owner or owners regarding the improvements in the process to prevent further incidents.

13.3.e. The program shall assure in the event of an incident or adverse event that:

13.3.e.1. The incident or adverse event is fully documented and appropriately reported to the correct state agencies as necessary;

13.3.e.2. There is prompt investigation and review of the situation surrounding the incident or adverse event;

13.3.e.3. Timely and appropriate corrective action is taken; and

13.3.e.4. Ongoing monitoring of any corrective action takes place until effectiveness of the action is established.

13.3.f. Within seven days of an incident or adverse event, the program shall file a report with the state oversight agency on the incident or adverse event consisting of the following:

13.3.f.1. The action or actions implemented to prevent the reoccurrence of the incident or adverse event;

13.3.f.2. The time frames for the action or actions to be implemented;

13.3.f.3. The person or persons designated to implement and monitor the action or actions;
and

13.3.f.4. The strategies for the measurements of effectiveness to be established.

13.3.g. The OBMAT program shall report any death involving drug overdose or drug-related complications to the state opioid treatment authority and the state oversight agency within 24 hours of the program receiving notification of the mortality.

13.3.h. A root-cause analysis shall be done for each incident or adverse effect.

§69-12-14. Staff Training and Credentialing

14.1. Each OBMAT program shall ensure that all doctors, physician assistants, advance practice registered nurses, licensed practical nurses, counselors, psychologists, marriage and family therapists, social workers and other licensed or certified professional care providers comply with the credentialing requirements of their respective professions, obtain and maintain a current license, and complete all continuing education requirements of the licensing board, W. Va. Code § 16-5Y-5(d) and this rule.

14.2. Clinical staff of an OBMAT program may include employees, independent contractors or both. The OBMAT program shall be responsible for ensuring that staff and contractors comply with all provisions of this rule. All clinical staff members and volunteers shall complete initial and continuing education and training that is specific to their job function, their interactions with patients, the pharmacotherapies to be used at the program, and the patient populations to be served.

14.3. Each OBMAT program shall develop detailed job descriptions for credentialed and non-credentialed staff and volunteers that clearly define the education, training, qualifications and competencies needed to provide specific services. The job descriptions shall be provided to and reviewed with all employees or volunteers at the time of the initial interview, upon employment and whenever there are significant changes in job assignment or a modification of the employee or volunteer's job description or responsibilities.

14.4. Within 10 days of the date any new clinical staff member or volunteer begins working at an OBMAT program, the program shall provide the staff member or volunteer with an orientation as to the person's primary job responsibilities and requirements. All clinical staff members and volunteers shall receive formal training in confidentiality issues and requirements prior to beginning work at the program.

14.5. Each OBMAT program shall maintain confidential individual personnel files for every clinical staff member or volunteer, that shall contain, at a minimum:

14.5.a. The application for employment, contract or request to work as a volunteer;

14.5.b. Documentation of the date of employment;

14.5.c. Identifying information and emergency contacts;

14.5.d. Documentation of completion of orientation, internal and external training and continuing education;

14.5.e. Documentation of all licenses, certifications or other credentials;

14.5.f. Documentation relating to performance, supervision, disciplinary actions and termination summaries; and

14.5.g. Detailed job descriptions.

14.6. The OBMAT program shall have a policy that delineates procedures governing disciplinary actions and non-voluntary termination of staff or volunteers.

§69-12-15. Risk Management.

15.1. Each OBMAT program shall:

15.1.a. Obtain a voluntary, written, program-specific informed consent to treatment from each patient at admission;

15.1.b. Inform each patient about all treatment procedures, services and other policies and procedures throughout the course of treatment;

15.1.c. Obtain voluntary, written, informed consent to the prescribed therapy from each patient before dosing begins;

15.1.d. Inform each patient that:

15.1.d.1. The goal of medication-assisted treatment is recovery, stabilization of functioning and establishment of a recovery-oriented lifestyle;

15.1.d.2. Detoxification from opioids or other substances is a treatment alternative to an ongoing, recovery-oriented plan of care, and that under the detoxification protocol:

15.1.d.2.A. The strength of maintenance doses of medication-assisted treatment medications should decrease over time, as clinically indicated; and

15.1.d.2.B. The participant is required to work toward a recovery-oriented lifestyle.

15.1.d.3. At each review of the individualized treatment plan of care, in full consultation with the patient, the program will discuss present level of functioning, course of treatment and future long-term recovery goals; and

15.1.d.4. A patient may choose to withdraw from or be maintained on the medication as he or she desires, unless medically contraindicated.

15.2. Each OBMAT program shall inform every patient regarding legal requirements and program policies concerning the report of suspected child abuse and neglect as well as other forms of abuse, such as violence against women.

15.3. Each OBMAT program shall inform every patient as to federal confidentiality regulations, 42 C.F.R. Part 2, and the Health Insurance Portability and Accountability Act of 1996, as amended.

15.4. Each OBMAT program shall:

15.4.a. Promulgate and make available a written description of patient rights and responsibilities;

15.4.b. Follow due process procedures and observe any applicable medical protocols for any involuntary terminations of patients;

15.4.c. Ensure that family members of employees do not receive special privileges; and

15.4.d. Monitor credentialing of all staff to ensure that they maintain current credentials for performing their assigned job duties.

§69-12-16. Medication Security, Storage, Administration and Documentation.

16.1. Medication Security.

16.1.a. Each OBMAT program shall develop and implement policies and procedures that comply with all relevant federal and state laws, rules and regulations regarding the storage and management of medications kept at the facility, if applicable, including measures that:

16.1.a.1. Ensure responsible handling and secure storage of all medications kept at the program;

16.1.a.2. Ensure responsible documentation of all medications received, stored, administered and dispensed at the program; and

16.1.a.3. Ensure that only authorized personnel may access the storage areas where any medications are kept.

16.2. Each OBMAT program shall have policies and procedures consistent with the DEA's statutes and regulations regarding the storage, administration and documentation of medications, if applicable.

16.3. Approved Medications.

16.3.a. An OBMAT program shall use only those medication-assisted treatment medications that are approved by the Food and Drug Administration under section 505 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355, for use in the treatment of substance use disorders.

16.3.b. The state opioid treatment authority is responsible for reviewing, monitoring, and approving, when applicable, practice guidelines for alternative treatments as they become available. The guidelines shall be in conformance with any nationally recognized guidelines approved by the secretary. The OBMAT program is responsible for remaining in conformity with practice guidelines as issued or approved by the state opioid treatment authority.

16.4. Dosage.

16.4.a. Each OBMAT program shall have a procedure through which the patient can discuss dosages of medication he or she receives with appropriate staff members regularly and upon request. This procedure shall be clearly described to the patient during orientation, upon admission and at least annually thereafter. A written explanation of the dosing procedures shall be initialed and dated by the patient and maintained in the patient chart and individualized treatment plan of care.

16.4.b. The maintenance dose of medication prescribed for a patient shall be individually determined in accordance with federal law and with guidelines and protocols from approved authorities. Adjustments upward or downward in dosage shall not be made either as punishment or reward, but shall be justified by the clinical documentation of the patient's condition, subjectively and objectively, in accordance with the approved guidelines and protocols.

16.4.c. Dosages of medication should be adjusted so that they shall ultimately:

16.4.c.1. Prevent the onset of subjective and objective signs of opioid or substance abstinence syndrome for 24 hours or more;

16.4.c.2. Reduce or eliminate drug cravings; and

16.4.c.3. Block the effects of illicitly acquired opioids without inducing persistent euphoric or other undesirable effects.

16.5. An OBMAT program and its physicians shall not dispense or administer medication-assisted treatment drugs on site.

16.6. All prescriptions for medication-assisted treatment medications may be issued by electronic prescribing, whenever possible.

16.7. Prescriptions for medication-assisted treatment medications shall include full identifying information for the patient, including full name and physical address; diagnosis code for which the medication is being prescribed; drug name, strength, dosage form, quantity and directions for use; the OBMAT program's license or registration number; and the prescribing program physician's regular DEA number and DATA 2000 identification number, if applicable.

§69-12-17. Continuous Quality Improvement Policies, Diversion Control Plan.

17.1. Each OBMAT program shall develop, implement and maintain current quality assurance and quality control plans that include provisions for:

17.1.a. Regular and continuous staff education;

17.1.b. An annual review, in consultation with the medical director and program physicians at an OBMAT program, of program policies and procedures;

17.1.c. A service delivery assessment which, at a minimum, shall evaluate appropriateness of the individualized treatment plan and services delivered, completeness of documentation in patients; records and quality of and participation in staff training programs, linkage to a utilization of primary care and other out-of-program services, and availability of services and medications for other conditions;

17.1.d. Consideration of ongoing input into program policies and procedures by patients regarding community concerns;

17.1.e. Development and implementation of annual patient satisfaction surveys that include a review of patient satisfaction;

17.1.f. Adherence to universal infection control precautions promulgated by the Center for Disease Control;

17.1.g. An ongoing assessment, measurement and monitoring of patient outcomes, treatment outcomes and the various processes including, but not limited to:

17.1.g.1. Reduction or elimination of the patient's use of illicit opioids, illicit drugs and the problematic use of licit drugs;

17.1.g.2. Reduction or elimination of associated criminal activities;

17.1.g.3. Reduction of the patient's behaviors contributing to the spread of infectious diseases;

17.1.g.4. Improvement of quality of life through the restoration of physical and behavioral health and functional status, including employment or volunteerism, as may be appropriate; and

17.1.g.5. Assessment of medication-related issues, including, but not limited to, take-home procedures, security, inventory and dosage issues.

17.2. The OBMAT program shall annually collect outcome measurements and results of patient satisfaction surveys. The medical director and program physicians at OBMAT programs shall review the results and submit the reports to the state opioid treatment authority.

17.3. Each OBMAT program shall participate in additional quality improvement outcome studies as directed by the designated state oversight authority.

17.4. An OBMAT program shall maintain a current "Diversion Control Plan" (DCP) as part of its quality assurance programs that contains specific measures to reduce the possibility of diversion of controlled substances from legitimate treatment use. The DCP shall assign specific responsibility to the medical and administrative staff of the OBMAT program for carrying out the diversion control measures and functions described in the DCP.

17.4.a. The DCP shall be reviewed and approved by the medical director and program physicians at OBMAT programs.

17.4.b. The DCP shall minimize the diversion of medication-assisted treatment medications to illicit use. The plan shall include:

17.4.b.1. Continuous clinical and administrative monitoring of the potential for and actual diversion including an investigation, tracking and monitoring system of incidents of diversion; and

17.4.b.2. Proactive planning and procedures for problem identification, correction and prevention.

17.4.c. The DCP shall contain, at a minimum, a random call-back program with mandatory compliance, which shall be in addition to the regular schedule of program visits.

§69-12-18. Patient Rights.

18.1. Each OBMAT program shall develop and implement policies and procedures which guarantee the following rights to patients:

18.1.a. To be informed, both verbally and in writing, of program rules and regulations and patient's rights and responsibilities. The rights and responsibilities shall be posted prominently and reviewed with the patient at admission, at the end of a stabilization period, at the time of an annual treatment review and at any time that changes in the rights and responsibilities occur;

18.1.b. To receive treatment provided in a fair and impartial manner regardless of race, sex, age, sexual orientation or religion;

18.1.c. To receive an individualized treatment plan of care developed according to guidelines established by a nationally recognized authority and approved by the secretary. The individualized treatment plan of care shall include a recovery model, shall be reviewed periodically by the program physician and counselor at OBMAT programs, and shall be maintained in the patient's chart;

18.1.d. To receive medications required by the individualized treatment plan of care on a schedule developed in accordance with applicable federal requirements and approved guidelines and protocols and that is the most accommodating and least intrusive and disruptive method of treatment for most patients;

18.1.e. To be informed that random drug testing of all patients shall be conducted during the course of treatment as required in section 33, and that any refusal to participate in a random drug test shall be considered a positive test. The patient shall be informed of the consequences of having a positive drug screen result;

18.1.f. To be entitled to participate in an OBMAT program that provides an adequate number of competent, qualified and experienced professional staff to implement and supervise the individualized treatment plan of care;

18.1.g. To be informed about potential interactions with and adverse reactions to other substances, including alcohol, other prescribed medications, over-the-counter pharmacological agents, other medical procedures, and food;

18.1.h. To be informed about the financial aspects of treatment, including the consequences of nonpayment of required fees;

18.1.i. To be given a copy of the initial assessment, written acceptance into the program; or, in the case of denial of admission, a full explanation as to the basis of the denial, and a referral to another OBMAT program based upon the results of the initial assessment;

18.1.j. To ensure confidentiality in accordance with federal regulations, 42 C.F.R. Part 2, and the Health Insurance Portability and Accountability Act of 1996, as amended;

18.1.k. To be informed of the extent of confidentiality, including the conditions under which information can be released without consent, the use of identifying information for the purposes of program evaluation, billing and statutory requirements for reporting abuse;

18.1.l. To give informed consent prior to being involved in research projects and the right to retain a copy of the informed consent form;

18.1.m. To receive full disclosure of information about treatment and medication, including accommodation for those who do not speak English, or who are otherwise unable to read an informed consent form; and

18.1.n. To be entitled to protection from other patients who act out. The program shall attempt to determine the cause of that behavior so that an appropriate referral to an alternative method of care can be made.

18.2. The OBMAT program shall have patient grievance procedures which shall be displayed in the patient care area in a conspicuous place and easily available to patients. They should include program

rules, consequences of noncompliance and procedures for filing a complaint or grievance. The procedures shall inform the patients of the following:

18.2.a. The right of a patient to express verbally or in writing his or her dissatisfaction with or complaints about treatment received;

18.2.b. The right of a patient to initiate grievance procedures without fear of reprisal;

18.2.c. The right of a patient to be informed of the grievance procedure in a manner that can be understood by the patient; and

18.2.d. The right of a patient to receive a decision in writing with the reasoning articulated.

18.3. Administrative withdrawal shall be used only as a sanction of last resort. It is the responsibility of the program to make every attempt before a patient is discharged to accommodate the patient's desire to be referred to an alternative treatment program as appropriate.

§69-12-19. Patient Records.

19.1. Each OBMAT program shall establish and maintain a recordkeeping system that is adequate to document and monitor patient care. The system shall comply with all federal and state reporting requirements relevant to opioid medications approved for use in treatment of substance use disorder.

19.2. All patient records shall be maintained for a minimum of five years from the time that the documented treatment is provided. In the event a patient is a juvenile, the records shall be kept for a minimum of five years from the time the patient reaches the age of 18.

19.3. All patient records shall be kept confidential in accordance with all applicable federal and state requirements.

19.4. All patient records shall be updated in a timely manner.

19.5. Information in the patient medical records shall be entered by designated program staff and approved by the program physician. Entries shall be legible and organized in an effective manner, allowing Materials to be easily retrieved.

19.6. OBMAT program policies and procedures should ensure security of all records including electronic records, if any.

19.7. Individual patient records shall contain:

19.7.a. Identifying and basic demographic data and the results of the screening process;

19.7.b. Documentation of program compliance with the program's policy regarding prevention of multiple admissions;

19.7.c. An initial assessment report;

19.7.d. A narrative biopsychosocial history completed within 30 days of the patient's admission;

19.7.e. All physical and biopsychosocial assessments completed every 90 days;

19.7.f. Medical reports including results of the physical examination; family medical history; review of systems; laboratory reports, including results of required toxicology screens; results obtained from the Controlled Substances Monitoring Program database; and progress notes, including documentation of current dose and other dosage data;

19.7.g. Dated case entries of all significant contacts with patients, including a record of each counseling session in chronological order;

19.7.h. Dates and results of case conferences for patients;

19.7.i. The initial and post-admission individualized treatment plans of care, and any amendments, reviews or changes to the plans;

19.7.j. Documentation that the services listed in the individualized treatment plan of care are available and have been provided or offered;

19.7.k. A written report of the treatment process; factors considered in decisions impacting patient treatment, e.g., take-home medication privileges, changes in counseling sessions, changes in frequency of toxicology screens; results from the Controlled Substances Monitoring Program database; documentation of whether the patient was offered or accepted a detoxification treatment plan option; and any other significant change in treatment, both positive and negative;

19.7.l. Coordination of care agreements signed by the patient, program physician and primary counselor;

19.7.m. Documentation that the OBMAT program made a good faith effort to review whether the patient is enrolled in any other OBMAT program;

19.7.n. A record of correspondence with the patient, family members and other individuals and a record of each referral for services and its results;

19.7.o. A record of correspondence with other health care providers of the patient;

19.7.p. Documentation that the patient was provided with a copy of the program's rules and regulations; a copy of the patient's rights and responsibilities; a copy of the detoxification treatment plan option, if applicable; a copy of the patient's individualized treatment plan of care; a copy of the patient's goals; and documentation that each of these items was discussed with the patient;

19.7.q. Consent forms, releases of information, prescription documentation, travel and employment; and

19.7.r. A closing summary, including reasons for discharge and any referral. In the case of death, the cause of death shall be documented.

19.8. Documentation of Patient Contact.

19.8.a. The primary counselor or medical staff is responsible for documentation of significant contact with each patient, which shall be filed in the patient record and include a description of:

19.8.a.1. The reason for or nature of the contact;

19.8.a.2. The patient's current condition;

19.8.a.3. Significant events occurring since prior contact;

19.8.a.4. The assessment of patient status; and

19.8.a.5. A plan for action or further treatment.

19.8.b. Each entry shall be completed by the next business day following of the contact and shall be clearly dated and initialed or signed by the staff person involved.

19.9. An OBMAT program that closes or discontinues OBMAT program services shall arrange for continued management of all patient records as follows:

19.9.a. The owner of the OBMAT program shall notify the secretary or his or her designee in writing of the address where records will be stored and specify the individual who will be managing records and that individual's contact information.

19.9.b. The owner of the OBMAT program shall arrange for the storage of each record through one or more of the following measures:

19.9.b.1. The owner of the OBMAT program shall continue to manage the records and give written assurance to the secretary or his or her designee that it will respond to authorized requests for copies of patient records within 10 working days.

19.9.b.2. The owner of the OBMAT program shall transfer records of patients who have given written consent to another OBMAT program; or

19.9.b.3. The owner of the OBMAT program will enter into an agreement with another OBMAT program to store and manage the patient records.

§69-12-20. Pre-Admission Assessment; Admission Criteria and Admission Process.

20.1. Each OBMAT program shall develop, implement and maintain policies and procedures designed to ensure that patients are admitted to maintenance treatment only after assessment by qualified personnel who have determined that the person meets the qualifications for admission.

20.2. Any individual seeking admittance to the OBMAT program shall undergo a pre-admission initial assessment in order to determine whether the person meets the criteria for admission to an OBMAT program. The initial assessment, consisting of a physical examination and an intake screening, shall be conducted by the medical director, an approved program physician or a supervised physician extender. The initial assessment shall focus on the individual's eligibility and need for treatment and shall provide indicators for initial dosage level, if required and if admission is determined appropriate. The determination of admission eligibility shall be made using accepted medical criteria such as those listed in the latest approved version of the Diagnostic and Statistical Manual for Mental Disorders.

20.3. The initial physical assessment shall include documentation of:

20.3.a. A brief physical examination;

20.3.b. The patient's immediately relevant history, including, but not limited to, determination of chronic or acute medical conditions such as diabetes, renal disease, hepatitis, sickle cell anemia, tuberculosis, human immunodeficiency virus (HIV) exposure, sexually transmitted disease, chronic cardiopulmonary disease and pregnancy;

20.3.c. A determination of currently prescribed medication or utilized over-the-counter substances;

20.3.d. An evaluation of the patient's use of other substances of abuse and alcohol;

20.3.e. Determination of current substance use disorder;

20.3.f. Determination of length of substance use disorder;

20.3.g. An initial drug test and full drug screen to identify whether the patient is using other drugs, including opiates, methadone, buprenorphine, amphetamines, cocaine, barbiturates, benzodiazepines, marijuana or other drugs or substances as determined by community standards, regional variation or clinical indication, such as carisopodol; to determine whether the individual has a substance use disorder from another OBMAT program;

20.3.h. An inquiry to and report from the Controlled Substances Monitoring Program database;

20.3.i. An inquiry whether the patient is enrolled in any other OBMAT program;

20.3.j. Identify comorbid medical and psychiatric conditions or disorders and to determine how, when and where they will be addressed;

20.3.k. Screen for communicable diseases and address them as needed and evaluate patient's level of physical, psychological and social functioning or impairment;

20.3.l. Assess the individual's access to social supports, family, friends, employment, housing, finances and whether any legal problems exist; and

20.3.m. Determine the patient's readiness to participate in treatment.

20.4. The individual desiring admission for treatment through the use of a medication-assisted treatment medication must be at least 18 years of age. Exceptions may be made on extremely rare occasions by application by the treating physician with parental consent to the state opioid treatment authority.

20.5. All admissions shall include documentation regarding medical necessity and program eligibility for medication-assisted treatment that includes:

20.5.a. Objective evidence, such as a positive drug test, of current physical dependence or tolerance to opioids or methadone; or

20.5.b. Objective symptoms of withdrawal, with documentation of the signs and symptoms of withdrawal, or both; or

20.5.c. Evidence from the patient of the following:

20.5.c.1. An onset of opioid physical dependence prior to admission with continuous use the greater part of the year; and

20.5.c.2. Evidence of multiple and daily self-administration of an opioid.

20.6. The following behavioral signs which support the diagnosis of substance use disorder shall be discussed and documented, although none are considered required for admission:

20.6.a. Unsuccessful efforts to control use;

20.6.b. Time spent obtaining drugs or recovering from the effects of abuse;

20.6.c. Continual use despite harmful consequences;

20.6.d. Obtaining opiates illegally;

20.6.e. Inappropriate use of prescribed opiates;

20.6.f. Giving up or reducing important social, occupational or recreational activities;

20.6.g. Continuing use of the opiate despite known adverse consequences to self, family or society; and

20.6.h. One or more unsuccessful attempts at gradual removal of physical dependence on opioids or detoxification using methadone, buprenorphine or other appropriate medications.

20.7. The absence of physiological dependence should not be an exclusion criterion, and admission may be clinically justified. The initial assessment may recognize that individuals in some populations may be susceptible to relapse to substance use disorder, leading to high-risk behaviors with potentially life threatening consequences.

20.8. After thorough review of the information acquired through the initial assessment, an individual may be admitted to the OBMAT program if, using accepted medical criteria, a determination is made that one or more of the following factors is met:

20.8.a. The individual is currently addicted to an opioid drug, as evidenced by a positive drug test for either opioids or methadone;

20.8.b. There are objective symptoms of withdrawal, or both; or

20.8.c. There is objective evidence that the individual qualifies under the provisions of section 20.9. of this rule.

20.9. Admission to the OBMAT program may be allowed to the following groups with a high risk of relapse without the necessity of a positive drug test or the presence of objective symptoms:

20.9.a. The individual is a pregnant woman with a history of substance use disorder;

20.9.b. The individual is a prisoner or has been released from a correctional facility within six months;

20.9.c. The individual is a former program patient who successfully completed treatment but believes that he or she is at risk of imminent relapse;

20.9.d. The individual is an HIV patient with a history of intravenous drug use; or

20.9.e. The individual has been deemed as high risk by the medical director or treating physician.

20.10. A patient enrolled in an OBMAT program shall not be permitted to obtain treatment in any other OBMAT program except in exceptional circumstances and only as provided in section 21 of these rules.

20.11. The admission and initial dosing of the patient may take place only after the patient is seen by a program physician, or an experienced medical professional working within the scope of his or her license who:

20.11.a. Has consulted by telephone or in person with the program physician;

20.11.b. Is approved by the medical director; and

20.11.c. Has completed a plan of development.

20.12. Whenever possible, the patient shall be admitted only after observation by and an interview with the program physician. Under unusual circumstances, an experienced medical professional working within the scope of his or her license may conduct the interview and observation and obtain telephone or fax orders from the physician to initiate treatment. Any patient admitted under those circumstances must be seen by the program physician within three working days of admission for verification of appropriate admission and treatment. All unusual circumstances and their outcomes shall be reviewed by the medical director at an OBMAT program.

20.13. The program physician or physician extender shall review the accumulated data directly with the individual and confirm a diagnosis of substance use disorder of sufficient severity to warrant admission to the OBMAT program. The program physician shall document that treatment is medically necessary. The admission and initial dosing decisions ultimately rest with the medical director or the designated program physician.

20.14. The program physician shall ensure that each patient voluntarily chooses maintenance treatment and that all relevant facts concerning the use of medication-assisted treatment medications are clearly and adequately explained to the patient. The program physician shall ensure that each newly admitted patient provides informed written consent to treatment.

20.15. Every individual shall be given the opportunity to enter into a detoxification program and shall be fully informed of the protocol, goals and procedures for detoxification. The individual shall

specifically consent to participation in the detoxification program in writing. The consent form shall be maintained in the patient chart and with the patient's individualized treatment plan of care.

20.16. Admission of individuals with no opioid tolerance shall require careful monitoring and documentation during the induction phase of treatment.

20.17. The physician or physician extender and patient shall each sign and date the verification that the initial assessment and review occurred and that the patient received all applicable information, policies and procedures.

20.18. Exceptions to admission policy shall be reviewed and tracked by medical director at an OBMAT program and be made available to regulatory bodies.

20.19. If a patient was previously discharged from treatment at another program, the admitting OBMAT program with patient consent shall contact the previous OBMAT program or programs for treatment history.

20.20. Non-admissions. The program shall maintain written logs that identify persons who were considered for admission or initially screened for admission but were not admitted. This log shall identify the reasons why the individuals were not admitted and what referrals were made for them by the program.

20.21. Patient Transfers.

20.21.a. OBMAT programs shall accept patients transferring from another OBMAT program within the state of West Virginia, if:

20.21.a.1. The OBMAT program accepting a patient voluntarily transferring from another OBMAT program shall provide documentation that the patient's medical record and reasons for the transfer was sought from the patient's previous OBMAT program; and

20.21.a.2. The patient is in compliance with readmission policies for patients who have been administratively detoxified.

20.21.b. In order for the patient to transfer to another OBMAT program, the following requirements shall be met:

20.21.b.1. The OBMAT program that the patient is leaving shall forward all relevant patient records to the OBMAT program where the patient is transferring; and

20.21.b.2. The OBMAT program shall provide documentation that the patient's medical record and reason for transfer was sought from the patient's previous OBMAT program and shall meet the admission criteria of this rule.

20.21.c. Patients who are West Virginia residents and wish to transfer to another West Virginia-based program shall be reviewed by the new program's admission program physician or medical director on an individual basis to determine their placement on the receiving program's patient listing. The review shall determine the patient's need, program placement availability and the circumstances for the transfer request.

20.21.d. Patients who are not West Virginia residents shall transfer to a West Virginia program as a new admission in accordance with this rule.

§69-12-21. Multiple Program Enrollments.

21.1. A patient enrolled in an OBMAT program shall not be permitted to obtain treatment in any other OBMAT program except in exceptional circumstances.

21.1.a. If the medical director or program physician of the OBMAT program in which the patient is enrolled determines that an exceptional circumstance exists, the patient may be granted permission to seek treatment at another OBMAT program.

21.1.b. The justification for finding exceptional circumstances shall be noted in the patient's individualized treatment plan of care and medical chart both at the OBMAT program in which the patient is enrolled and at the OBMAT program that provides the additional treatment.

21.2. When practicable, the OBMAT program shall obtain a written consent for release of information from the patient in order to check the records of every OBMAT program within 100 miles of the program site so as to ensure that the patient is not currently enrolled in those programs as well. The request for information may be made by telephone, fax or e-mail. The release of information shall state that only prior admissions may be the subject of inquiry, not contacts without admission. The OBMAT program shall protect patient confidentiality at all times and with all procedures used in acquiring medical or health information.

21.3. Results of the multiple-program check shall be contained in the clinical record, the patient chart and the individualized treatment plan of care.

21.4. A multiple program enrollment check shall be repeated if the patient is discharged and readmitted at any time.

§69-12-22. Controlled Substances Monitoring Program Database.

22.1. Each OBMAT program shall comply with policies and procedures developed by the designated state oversight agency and the West Virginia Board of Pharmacy to allow physicians treating patients through an OBMAT program access to the Controlled Substances Monitoring Program database maintained by the West Virginia Board of Pharmacy.

22.2. Program physicians shall access the database:

22.2.a. At the patient's intake;

22.2.b. Before the administration of medication-assisted treatment medications or other treatment in an OBMAT program;

22.2.c. After the initial 30 days of treatment;

22.2.d. After any positive drug test; and

22.2.e. At each 90-day treatment review.

22.3. The program physician shall access the Controlled Substances Monitoring Program database in order to ensure that the patient is not seeking prescription medication from multiple sources. The results obtained from the database shall be maintained with the patient records.

§69-12-24. Orientation.

24.1. Every person admitted to an OBMAT program shall receive program orientation. The orientation shall be made verbally at the earliest opportunity at which the patient is stable and capable of understanding and retaining the information presented. Information provided in the orientation shall be given to the patient in writing at the time the decision is made to admit the patient, regardless of his or her condition, and shall include a formal agreement of informed consent to be signed by the patient.

24.2. Orientation shall include the following:

24.2.a. An explanation of the rights and responsibilities of the patient.

24.2.b. An explanation of the patient's right to file a grievance and applicable appeal procedures.

24.2.c. An explanation of the services and activities provided by the OBMAT program, either onsite or by referral, including:

24.2.c.1. Expectations and rules;

24.2.c.2. Hours of operation;

24.2.c.3. Access to after-hours services;

24.2.c.4. Confidentiality policy;

24.2.c.5. Toxicological screening and random drug-testing policies;

24.2.c.6. Sanctions, restrictions and other penalties;

24.2.c.7. Interventions;

24.2.c.8. Incentives; and

24.2.c.9. Various discharge criteria, including, but not limited to, administrative and medical withdrawal policies and procedures.

24.2.d. An explanation about obtaining reports from the Controlled Substances Monitoring Program database; how the reports are used to treat and monitor the patient and the requirement that the reports be maintained in the patient files.

24.2.e. An explanation of any and all financial obligations of the patient; all fees charged by the OBMAT program; and any financial arrangements for services provided by the OBMAT program, including the requirements stated in W. Va. Code § 16-5Y-5(e).

24.2.f. Familiarization with the OBMAT program facility and premises.

24.2.g. A description of the OBMAT program's policies regarding:

24.2.g.1. Use of alcohol on or prior to entering the facility and premises;

24.2.g.2. Smoking;

24.2.g.3. Illicit or licit drugs brought into the program or onto the premises; and

24.2.g.4. Weapons brought into the program or onto the premises.

24.2.h. Identification of the counselor assigned to the patient and contact information for that counselor.

24.2.i. A copy of the OBMAT program rules identifying the following:

24.2.i.1. Any restrictions the program may place on the patient;

24.2.i.2. Events, behaviors or attitudes that may lead to the loss of rights or privileges for the patient; and

24.2.i.3. Means by which the patient may regain rights or privileges that have been restricted;

24.2.j. An explanation of the purpose and process of the initial and subsequent physical and biopsychosocial assessments;

24.2.k. A description of how the individualized treatment plan of care and coordination of care agreement will be developed and the patient's expected participation in the plan of care; and

24.2.l. An explanation of alternative methods that are available for treatment of substance use disorder, whether offered by the program or not, and the potential benefits and risks.

24.3. Upon admission, each patient shall receive the following written information:

24.3.a. Signs and symptoms of overdose and when, where and how to seek emergency assistance;

24.3.b. A formal agreement of informed consent to be signed by the patient;

24.3.c. A signed of the coordination of care agreement;

24.3.d. Patient's rights;

24.3.e. Confidentiality policies;

24.3.f. The program's processes for dispensing medication; and

24.3.g. Information on alternative methods available for treatment of substance use disorder and the potential benefits and risks. The state opioid treatment authority is responsible for providing informational materials to be used in discussing alternative treatments.

24.4. As soon as the patient is stable and capable of understanding, the patient shall receive group or individual education on the following:

24.4.a. Medication administration, including methods of dispensing and dosage restrictions;

24.4.b. The nature of substance use disorder including the great likelihood that substance use disorder is a relapsing disease and is likely to have grave medical and social consequences if not treated on an ongoing basis;

24.4.c. The anticipated benefits of treatment;

24.4.d. The nature of the recovery process;

24.4.e. HIV spectrum and other infectious diseases;

24.4.f. Potential drug interactions;

24.4.g. Self-help groups;

24.4.h. Medical issues related to detoxification from medication-assisted treatment medications;

24.4.i. The special risk of withdrawal from the medication-assisted treatment medication prescribed to the individual patient and detoxification to pregnant women and the fetus, as appropriate;

24.4.j. Characteristics of the medications administered or prescribed by the program;

24.4.k. Drug safety issues;

24.4.l. Dispensing procedures; and

24.4.m. Side effects of medications administered or prescribed by the program.

24.5. Documentation that the patient has completed the orientation training shall be completed and signed by the patient and maintained in the patient's chart and individualized treatment plan of care.

§69-12-25. Required Services.

25.1. Each OBMAT program shall provide adequate medical, counseling, vocational, educational, recovery and other assessment and treatment services. These services must be available onsite at the facility or on a referral basis to outside providers and the medical director at an OBMAT program must be able to document that these services are fully and reasonably available to patients and comply with all federal and state laws, rules and regulations.

25.2. Each OBMAT program shall require every patient to undergo a documented physical assessment by a program physician or a physician extender under the supervision of a program physician, before admission to the OBMAT program. The full medical examination shall be completed at the time of admission and prior to the first dose of medication-assisted treatment medication. The results of serology, toxicology and other tests must be completed within 14 days following admission.

25.3. Each OBMAT program shall require every patient to undergo a complete, fully documented biopsychosocial assessment by a program counselor before admission to the OBMAT program. The full biopsychosocial assessment shall be completed at the time of admission and prior to the first dose of medication-assisted treatment medication.

25.4. Each patient accepted for treatment at an OBMAT program shall be assessed including physical and biopsychosocial assessments initially and at least every 90 days following the initial assessment by qualified personnel who shall determine the most appropriate combination of recovery-oriented services and treatment for the patient.

25.5. Within seven days of the admission of a patient, the OBMAT program shall complete a post-admission initial assessment, an initial individualized treatment strategy or plan of care and a coordination of care agreement.

25.6. Random drug testing of all patients shall be conducted during the course of treatment as required in section 33. Each OBMAT program must provide adequate testing or analysis for drugs of abuse in accordance with generally accepted clinical practice.

25.7. Each OBMAT program must provide adequate substance use disorder counseling to each patient as clinically necessary and at the minimum levels as required by section 26.8 of this rule. Counseling shall be provided by a program counselor, qualified by education, training or experience to assess the psychological and sociological background of patients, to contribute to the appropriate individualized treatment plan of care for the patient and to monitor patient progress.

25.8. Each OBMAT program shall maintain current policies and procedures that reflect the special needs of patients who are pregnant. Prenatal care and other gender-specific services of pregnant patients must be provided either by the OBMAT program or by referral to appropriate health care providers. Services rendered to pregnant patients shall comply with the requirements of section 34.5 of this rule.

25.9. Each OBMAT program shall provide counseling on preventing exposure to, and the transmission of, HIV and hepatitis C for each patient admitted or re-admitted to maintenance or detoxification treatment. Services rendered to patients with HIV disease shall comply with the requirements of section 34.3 of this rule.

25.10. Each OBMAT program that provides required services by referral or other agreement at offsite facilities or providers shall:

25.10.a. Establish a strong working relationship with several treatment providers offering different levels of treatment;

25.10.b. Be able to document a referral or other agreement with a local hospital, health care facility or other provider that provides offsite services for the OBMAT program;

25.10.c. Review psychosocial treatment expectations and responsibilities with the patient;

25.10.d. Obtain signed consent form from each patient to approve open communication with the offsite provider and the OBMAT program; and

25.10.e. Routinely provide and obtain updates from offsite providers to consistently monitor treatment attendance and progress.

25.11. Services provided by an OBMAT program should adhere to recovery initiatives promoted by federal and state laws, rules and regulations and the protocols and guidelines of approved authorities. Recovery initiatives include assistance in overcoming or managing a patient's substance use disorder or other diseases; encouraging a patient to live in a physically and emotionally healthy manner; ensuring that the patient lives in a stable and safe place; engaging the patient in meaningful daily activities, such as job, school, volunteerism, family caretaking or creative endeavors; and assisting the patient in obtaining the independence, income and resources to participate in society and in developing relationships and supportive social networks.

§69-12-26. Counseling.

26.1. Each OBMAT program shall provide substance use disorder counseling to every patient as is clinically appropriate. Counseling sessions should encourage and guide the patient to a lifestyle that does not include abuse or misuse of prescribed and illicit medications, drugs or other substances. Counseling sessions are essential to promote and guide the patient to a more productive lifestyle of abstinence from illicit medications or drugs.

26.2. The counseling shall be provided by a counselor or other professional as described in this rule, qualified by education or training to assess the psychological and sociological background of patients, to contribute to the appropriate individualized treatment plan for the patient, and to monitor patient progress. The primary counselor shall develop and implement the psychological and social portions of the patient's individualized treatment plan of care, in coordination with the medical staff and program physician. The individualized treatment plan of care shall address the social, environmental, psychological, social and familial issues relative to recognizing, correcting and eliminating the individual's maladaptive patterns of drug consumption and other high risk or destructive behaviors.

26.3. The primary counselor is responsible for assisting the patient in altering lifestyles and patterns of behavior in order to improve the individual's ability to function adaptively in his or her family and community. Counseling shall address the social, environmental, psychological and familial issues that contribute to the individual's maladaptive patterns of drug consumption and other high risk or destructive behaviors.

26.4. Each OBMAT program shall provide counseling on matters indirectly related to substance use disorder, including, but not limited to:

26.4.a. Preventing exposure to, and the transmission of, HIV and hepatitis C for each patient admitted or readmitted to maintenance or detoxification treatment; and

26.4.b. Domestic violence, sexual abuse and anger management.

26.5. Each OBMAT program shall develop and implement policies and procedures which ensure that single sex groups or same sex counselors will be available to all patients, as warranted or requested and clinically indicated.

26.6. Each OBMAT program must provide directly, or through referral to adequate and reasonably accessible community resources, vocational rehabilitation, education and employment services for patients who either request such services or who have been determined by the program staff to be in need of such services.

26.7. The clinical staff caseload ratio as defined in section 7.5.c. shall:

26.7.a. Reflect an appropriate clinical mix of gender, race and ethnicity representative of the population served;

26.7.b. Allow the program to provide adequate psychosocial assessments, treatment planning and individualized counseling;

26.7.c. Allow for regularly scheduled, documented individual counseling sessions as clinically indicated; and

26.7.d. Allow patients access to their primary counselor if more frequent contact is merited by need or is requested by the patient.

26.8. Counseling sessions shall be provided according to generally accepted best practices and shall be offered:

26.8.a. At least twice weekly during the first 30 days of treatment;

26.8.b. At least weekly during the next 90 days of treatment;

26.8.c. At least twice per month during the remainder of the first year of treatment; and

26.8.d. Thereafter, for subsequent 90-day periods of treatment, counseling sessions shall take place as needed or indicated in the patient's individualized treatment plan of care, but not less frequently than monthly as long as the patient is compliant.

26.9. The counseling program shall provide for mandatory and documented weekly counseling of any patient who has a positive drug test and is required by this rule to undergo additional counseling. The counseling sessions shall be no less than 30 minutes to a patient with a counselor or other professional as described in section 7.5, whichever is applicable, of this rule who is licensed, certified or enrolled in the process of obtaining licensure, registration or certification. The mandatory counseling sessions may consist of group counseling sessions. However, the patient must attend at least one individual, private session per month.

26.11. All counseling sessions shall be contained in the OBMAT program's patient record and shall include documentation of the following:

26.11.a. The reason for or nature of the contact;

26.11.b. The patient's current condition;

26.11.c. Significant events occurring since the prior contact;

26.11.d. The assessment of the patient's status; and

26.11.e. A plan for action or further treatment that addresses the goals of the individualized treatment plan of care.

26.12. Each counseling session shall be documented and completed within 72 hours of the contact and shall be clearly dated and initialed or signed the counselor providing the counseling session.

26.13. Counseling session opportunities for family or significant other involvement in counseling shall be provided and documented.

26.14. If counseling is not directly provided through the OBMAT program, the counselor(s) shall still meet the credentialing requirements pursuant to this rule and verification of all sessions must be documented in the MAT patient record.

§69-12-27. Provision of Coordination of Patient Care; Post-Admission Assessment and Initial Plan of Care.

27.1. Each OBMAT program shall develop, implement and maintain current policies and procedures, patient protocols, treatment plans and profiles for the treatment of patients seeking treatment for medication-assisted treatment.

27.2. Initial Post-Admission Assessments.

27.2.a. All patients shall undergo an initial post-admission assessment in order to determine the patient's condition, diagnosis and treatment. The assessment shall be conducted by one or more program physicians.

27.2.b. Upon admission to an OBMAT program, each patient shall undergo an initial post-admission assessment and the OBMAT program shall develop an initial plan of care. The initial assessment and plan of care shall be completed within seven days of the patient's admission.

27.2.c. The initial post-admission assessment shall consist of a comprehensive medical assessment and include documentation of:

27.2.c.1. A physical assessment by a qualified medical professional within their scope of practice;

27.2.c.2. A psychiatric assessment, including mental status examination and psychiatric history;

27.2.c.3. A personal and family medical and health history;

27.2.c.4. All current medications, prescription or otherwise;

27.2.c.5. A comprehensive history of substance abuse, both personal and family;

27.2.c.6. Determination of current dependence on controlled substances;

27.2.c.7. A tuberculosis screening;

27.2.c.8. A screening test for syphilis;

27.2.c.9. A hepatitis C test;

27.2.c.10. An HIV test to the extent voluntarily elected by the patient;

27.2.c.11. An inquiry to and report from the Controlled Substances Monitoring Program database;

27.2.c.12. Laboratory tests;

27.2.c.13. A full drug screen;

27.2.c.14. An inquiry whether the patient is being treated at any other OBMAT program;

27.2.c.15. The diagnosis of all conditions, including a diagnosis of substance use disorder, including signs and symptoms;

27.2.c.16. A copy of the report by the referring physician and any medical records from other providers, if applicable;

27.2.c.17. The dates, amounts and dosage forms for any drugs prescribed, dispensed and administered; and

27.2.c.18. Other tests as necessary or appropriate, including, but not limited to, CBC, EKG, X-ray, pap smear, hepatitis B surface antigen and hepatitis B antibody testing.

27.2.d. A program physician or supervised physician extender shall perform a physical assessment of a patient on the same day that the program physician initially prescribes, dispenses or administers a medication-assisted treatment medication to a patient. If the patient continues to be treated for substance use disorder at the program, a physical assessment shall be performed at least every 90 days thereafter. All examinations shall be performed according to accepted and prevailing standards for medical care.

27.2.e. A repeat, full toxicology screen may be completed at 14 days after admission to identify whether the patient is using other drugs or substances, including, but not limited to, opiates, methadone, buprenorphine, amphetamines, cocaine, barbiturates, benzodiazepines and marijuana.

27.2.f. The initial post-admission assessment may include laboratory tests conducted by the OBMAT program or by other reliable sources.

27.2.f.1. Laboratory tests that are not directly conducted by the OBMAT program may be provided by the patient's primary care physician, other health care providers or by a medical clinic.

27.2.f.2. The OBMAT program is responsible for obtaining and maintaining documentation of required laboratory tests performed by an alternative provider. Alternative providers may not supply toxicology screens unless they meet the required quality guidelines, content and timelines.

27.2.f.3. Tests not directly conducted by the OBMAT program at admission shall have been conducted within the 27 days prior to the admission in order to be considered a valid assessment of the patient.

27.3. Continued Post-Admission Assessments.

27.3.a. Subsequent patient assessments shall include documentation of:

27.3.a.1. Follow-up physical examinations, by a program physician or a supervised physician extender;

27.3.a.2. The patient's response to treatment;

27.3.a.3. Any modification to the plan of treatment;

27.3.a.4. The dates on which any medications were prescribed, dispensed or administered;

27.3.a.5. The amounts and dosage forms for any drugs prescribed, dispensed or administered;

27.3.a.6. Laboratory tests; and

27.3.a.7. Full toxicology screens.

27.4. Initial Plan of Care.

27.4.a. The treating program physician and other health care professionals, working within their scope of practice, directly involved in the care of the patient shall develop a written initial plan of care for every patient.

27.4.b. The initial plan of care shall include, at a minimum:

27.4.b.1. Information required for the initial assessment;

27.4.b.2. Documentation of the patient's diagnoses, the proposed medical and medication-assisted treatment, medication dosages and administration;

27.4.b.3. Documentation of the patient's current physical condition and whether the patient requires other health care;

27.4.b.4. Laboratory test results;

27.4.b.5. Follow-up on any identified medical, physical or behavioral health issues;

27.4.b.6. Documentation of any education regarding the OBMAT program's policies and procedures, substance use disorder or counseling sessions and resolution of other issues unique to the needs of the individual patient;

27.4.b.7. Such other information as recommended by the guidelines and treatment model utilized for the patient;

27.4.b.8. Specific goals and outcomes to improve or maintain the optimal health of the patient which are based on the assessment of the patient; and

27.4.b.9. A description of services and their frequency to be provided for the patient and primarily directed to achieve the expected goals and outcomes.

§69-12-28. Comprehensive Physical and Biopsychosocial Evaluations.

28.1. Within 30 days after admission, or when the patient is stable and able to fully participate, the program shall complete a physical and biopsychosocial evaluation, or, if an OBMAT program, refer the patient to an outside provider for same, which shall be used to develop the long-term individualized treatment plan of care. The physical and biopsychosocial evaluations shall integrate information obtained in all treatment of the patient at the OBMAT program.

28.2. The physical and biopsychosocial evaluations shall include information obtained from:

28.2.a. The patient;

28.2.b. Family members, when applicable and permitted;

28.2.c. Friends and peers, when appropriate and permitted; and

28.2.d. Other appropriate and permitted collateral sources.

28.3. The comprehensive physical evaluation shall include information regarding the following:

28.3.a. A physical examination;

28.3.b. An update to any immediate relevant history, including, but not limited to, the determination of chronic or acute medical conditions such as diabetes, renal disease, hepatitis, sickle cell anemia, tuberculosis, HIV exposure, sexually transmitted disease, chronic cardiopulmonary disease and pregnancy;

28.3.c. A determination of currently prescribed medications or utilized over-the-counter substances;

28.3.d. A determination and evaluation of the patient's use of other substances of abuse and alcohol;

28.3.e. A toxicology screen;

28.3.f. An inquiry to and report from the Controlled Substances Monitoring Program database;

28.3.g. An inquiry whether the patient is enrolled in any other OBMAT program;

28.3.h. Screen for communicable disease and address them as needed and evaluate patient's level of physical, psychological and social functioning or impairment; and

28.3.i. Assess the individual's access to social supports, family, friends, employment, housing, finances and whether any legal problems exist.

28.4. The comprehensive biopsychosocial evaluation shall include information about the patient's:

28.4.a. Personal strengths;

28.4.b. Individualized needs;

28.4.c. Abilities or interests;

28.4.d. Presenting problems, including a thorough analysis of the individual's substance use disorders such as, licit and illicit drugs used, including alcohol; amounts of drugs or alcohol used; frequency of use; duration of use; symptoms of physical addiction; history of treatment for substance use disorder; adverse consequences of use; inappropriate use of prescribed substances; and urgent needs, including suicide risk;

28.4.e. Previous behavioral health services, including diagnostic information; treatment information; efficacy of current or previously used medication; physical health history and current status; diagnoses; mental status and current level of functioning;

28.4.f. Pertinent current and historical life situation information, including the patient's age; gender; employment history; involvement in legal proceedings; family history; history of abuse or neglect; and relationships, including natural supports;

28.4.g. Use of alcohol and tobacco;

28.4.h. Need for, and availability of, social supports;

28.4.i. Risk-taking behaviors;

28.4.j. Level of educational functioning;

28.4.k. Medications prescribed that are not a target of treatment or concern;

28.4.l. Medication allergies or adverse reactions to medications;

28.4.m. Adjustment to disabilities or disorders; and

28.4.n. Motivation for treatment.

28.5. The patient's primary counselor shall review the biopsychosocial assessment and prepare a concise, interpretive multidisciplinary summary that:

28.5.a. Is based on the assessment data;

28.5.b. Describes and evaluates the level and severity of the individual's substance use disorder behaviors;

28.5.c. Is used in the development of the individualized treatment plan of care; and

28.5.d. Identifies any co-occurring disabilities or disorders that should be addressed in the development of the individualized treatment plan of care.

§69-12-29. Individualized Treatment Plan of Care.

29.1. Delivery of patient care and treatment interventions shall be based on the needs identified in the individualized treatment plan of care.

29.2. Within 30 days after admission of a patient, the OBMAT program shall develop a more comprehensive individualized treatment plan of care and attach it to the patient's chart no later than five days after the plan is developed. The individualized treatment plan of care shall be developed pursuant to the guidelines and protocols established by the American Society of Addiction Medicine (ASAM), the Center for Substance Abuse Treatment (CSAT) and the National Institute on Drug Abuse (NIDA), the American Association for the Treatment of Opioid Dependence (AATOD), or such other nationally recognized authority approved by the secretary. The individualized treatment plan of care shall include a recovery model based upon the approved guidelines and protocols.

29.3. The individualized treatment plan of care shall be reviewed by the program physician, primary counselor and patient at least every 90 days and documented in the patient record. Reviews shall address each of the objectives identified on the initial plan of care; document all treatment, counseling, medications and other services rendered to the patient; and document the patient's progress. A revised plan of care may be implemented with each review. If a new plan of care is not implemented, the reasons for such decision should be documented in the patient's record. Paper and electronic plans of care, including all reviews and updates, must be acknowledged by the patient.

29.4. The initial and quarterly individualized treatment plans of care shall be developed by the patient, the program physician and primary counselor, with input as appropriate from other health care providers. The individualized treatment plan of care shall be drafted to meet the specific needs of the patient. After the individualized treatment plan of care is developed and approved by the patient, the plan of care shall be placed in the patient's chart within five days of development. The patient shall receive a copy of all of his or her individualized treatment plans of care.

29.5. All individualized treatment plans of care shall include, at a minimum:

29.5.a. Documentation of the patient's diagnoses; the proposed medical treatment and counseling; medication dosages and administration;

29.5.b. A requirement that the patient regularly attend and participate in the OBMAT program, both medical and counseling aspects, as determined necessary by the staff and patient;

29.5.c. The identification of "triggers" for misuse of substances;

29.5.d. The development and use of coping strategies for each "trigger";

29.5.e. The development of a detailed relapse prevention plan;

29.5.f. Meaningful follow-up on any identified behavioral health issues;

29.5.g. Follow-up medical or physical issues as necessary;

29.5.h. A vocational evaluation, formal or informal;

29.5.i. A plan to achieve financial stability and independence;

29.5.j. A requirement that the patient abstain from use of illicit substances, abuse of prescription substances or other substances of abuse;

29.5.k. Documentation of other individual or familial issues as relevant and appropriate and the proposed means of addressing such issues;

29.5.l. The success of the patient's treatment, initiatives and goals;

29.5.m. A description of services and their frequency to be provided for the patient and primarily directed to achieve the expected goals and outcomes;

29.5.n. The results from initial, monthly and random drug tests; and

29.5.o. Such other information as recommended by the guidelines and recovery model utilized for the patient.

29.6. The individualized treatment plan of care shall reflect the patient's current physical health condition and whether the patient requires other health care services. OBMAT programs without primary care services onsite shall refer patients for appropriate laboratory tests and additional medical treatment and follow up on the results.

29.7. Each OBMAT program shall provide opportunities for family involvement in the therapy provided to each patient and document such involvement in the individualized treatment plans of care.

29.8. The medical staff shall conduct careful discussions with the patient regarding the patient's continued desire to remain in the OBMAT program on a maintenance schedule of medication and document such discussions in the patient's chart and individualized plans of care.

29.8.a. OBMAT programs shall make every effort to retain patients in treatment as long as clinically appropriate and medically necessary in accordance with approved national guidelines and acceptable to the patient.

29.8.b. At the time of the quarterly review, the patient shall again be presented with the option of participating in alternative treatment, such as medically-supervised withdrawal. The patient shall sign and date a statement indicating whether he or she wishes to participate in an alternative form of treatment or remain within the program in an ongoing recovery-oriented maintenance format. The statement shall be included with the patient's individualized treatment plan of care.

29.8.c. If the patient chooses the option of participating in alternative treatment, the individualized treatment plan of care shall include a consent form signed by the patient acknowledging

that under the detoxification protocol the strength of maintenance doses of medication-assisted treatment medication should decrease over time and that the participant is required to work toward a recovery-oriented lifestyle.

29.8.d. A patient in good standing with the program, as defined by policy, has the right to continue to stay in the program. At no time should such a patient feel pressured to enter a program of withdrawal over his or her objections.

29.8.e. If a patient wishes to enter medically-supervised withdrawal, the individualized treatment plan of care shall reflect that choice.

29.8.f. If at any time a patient in good standing wishes to re-enter a maintenance program, the patient may do so in consultation with the primary counselor and medical staff.

29.9. With the patient's permission, the OBMAT program shall obtain complete medical records from other providers and maintain the records in the patient's chart and the individualized treatment plan of care.

29.10. Coordination of Care Agreement.

29.10.a. The coordination of care agreement shall be signed by the patient, program physician and primary counselor. If a change of program physician or primary counselor takes place, a new agreement must be signed.

29.10.b. The coordination of care agreement shall be reviewed and updated at least annually. If the coordination of care agreement is reviewed, but not updated, the review shall be documented in the patient's record.

29.10.c. The coordination of care agreement shall include the following:

29.10.c.1. An authorization allowing communication between the program physician and primary counselor so that the patient may receive comprehensive and quality medication-assisted treatment;

29.10.c.2. The name and contact information for the program physician and primary counselor;

29.10.c.3. The categories of records which may be shared;

29.10.c.4. A summary of treatment and goals, diagnoses and services to be received onsite or by referral;

29.10.c.5. Current medications being prescribed, including dosage, frequency and delivery;

29.10.c.6. Date and prescription history for medication-assisted treatment medications; and

29.10.c.7. Estimated length of treatment.

29.10.d. The coordination of care agreement will be provided in a form prescribed and made available by the secretary.

§69-12-30. Detoxification Program.

30.1. In addition to recovery-oriented medication-assisted treatment services, each OBMAT program shall provide both long-term and short-term detoxification recovery treatment services, either onsite or by referral. The program physician or a physician extender shall provide onsite medical supervision and oversight of the detoxification treatment program. If detoxification treatment is provided by referral, the program physician shall maintain documentation and communication with the referred detoxification program and keep such documentation in the patient's record.

30.2. All potential patients shall be offered the opportunity to participate in either a recovery-oriented long-term detoxification treatment services plan or a short-term detoxification services plan of varying durations. A detoxification treatment services plan shall be implemented only if agreed upon by the patient and deemed appropriate by the physician or physician extender through utilizing and applying established diagnostic criteria.

30.3. Patients with two or more unsuccessful detoxification episodes within a 12-month period must be assessed by the OBMAT program physician for other forms of treatment. A program shall not admit a patient for more than two detoxification treatment episodes in one year. One year of physiologic dependence is not required for detoxification treatment although documentation of current dependency is required.

30.4. The patient's individualized treatment plan of care shall state whether the patient chose detoxification treatment services and, if so, whether the patient selected the short-term or long-term detoxification treatment program. If the patient selected the option for detoxification treatment services, the patient's chart shall include a consent form signed by the patient reflecting selection of such an option. The consent form shall include the patient's acknowledgement that under the detoxification protocol the strength of maintenance doses of medication-assisted treatment medications should decrease over time; that the treatment period should be in accordance with national guidelines; and that the patient is required to work toward a recovery-oriented lifestyle.

30.5. The estimated time of detoxification required to reach the point of elimination of the medication shall be specified by the physician and documented in the patient's individualized treatment plan of care. The titration schedule may be modified at any time. Any extension or modification of the titration schedule shall be documented in the patient's individualized treatment plan of care and chart.

30.6. The program physician shall determine on an individualized basis the appropriate dosage of medication-assisted treatment medication to ensure stabilization during detoxification. The determination shall be based upon individual clinical data in accordance with guidelines and protocols established by approved authorities.

30.7. Exceptions to treatment guidelines or a patient's refusal to participate in the program shall be documented and tracked by the program.

30.8. Urine or other toxicological screening instruments shall be used by the OBMAT program staff during detoxification treatment in order to demonstrate the absence of use of alternative licit or illicit drugs.

30.9. The OBMAT program shall develop and implement a policy regarding recovery-oriented detoxification treatment from medication-assisted treatment medication that shall include:

30.9.a. Individualized determination of a schedule of detoxification that is well tolerated by the patient and consistent with approved national guidelines and sound medical practices;

30.9.b. Implementation of a higher stabilizing dose in the event of impending relapse as appropriate and possible;

30.9.c. Assurances that voluntary detoxification shall be discontinued in the event of relapse and that provisions for maintenance treatment shall be made;

30.9.d. Evaluation or testing for pregnancy prior to detoxification; and

30.9.e. Provision for continuing care after the last dose of methadone or other medication-assisted treatment medication.

30.10. The OBMAT program shall have procedures for providing detoxification treatment services to persons prior to their incarceration in criminal justice system facilities if possible and foreseeable. When appropriate, the OBMAT program shall have cooperative agreements with the criminal justice system to encourage detoxification treatment services to persons who are incarcerated or on probation or parole and are required to become abstinent.

30.11. Short-Term Detoxification Treatment Services.

30.11.a. Short-term detoxification treatment services are those services projected to last fewer than 30 days.

30.11.b. Unsupervised doses of medication may not be administered to patients admitted for short-term detoxification unless the patient qualifies under a federal or state-approved exemption and there is a verifiable emergency. If there is a verifiable exemption or emergency, the OBMAT program shall not allow the patient more than one unsupervised or take home medication dose per week. If the program operates on a seven day-per-week basis, no take home, unsupervised medications shall be allowed except on permitted holidays or closures or pursuant to an authorized exemption.

30.11.c. For a patient admitted for detoxification treatment services for 14 days or less, the program must offer a minimum of four counseling sessions per week.

30.12. Long-Term Detoxification Treatment Services.

30.12.a. Long-term detoxification treatment services are those services projected to last more than 30 and up to 180 or more days, depending on clinical need.

30.12.b. Frequency of access to unsupervised medications shall be determined by the program physician in accordance with federal law and guidelines and protocols from an approved authority.

30.12.c. In a detoxification program of more than 30 days' duration, the OBMAT program shall have a policy that grants the patient the opportunity to receive take home medications. No unsupervised take home medications may be administered or prescribed for a patient during the first 30 days of treatment unless the patient qualifies under an approved exemption or emergency. Thereafter, based upon federal law, approved national guidelines and the clinical judgment of the program physician, the quantity of unsupervised medication shall not exceed the following doses:

30.12.c.1. One unsupervised dose per week for the remaining 60 days of the first 90-day treatment plan. Provided, that in a week in which a holiday causes the OBMAT program to be closed, two doses may be allowed.

30.12.c.2. Two unsupervised doses per week during the second 90 days of treatment.

30.12.c.3. Three unsupervised doses per week during third 90 days of treatment.

30.12.c.4. A maximum six-day supply of take home medication in the remaining months of the first year of treatment.

30.13. Counseling Services.

30.13.a. Counseling services provided in conjunction with detoxification treatment services shall be designed to:

30.13.a.1. Explore other modalities of care, including drug and alcohol treatment following detoxification or discharge;

30.13.a.2. Motivate the patient to continue to receive services or to develop a plan for recovery following discharge; and

30.13.a.3. Identify triggers for relapse and a coping plan for dealing with each, detailed and in writing and given to the patient prior to discharge.

30.13.b. The counseling plan shall be developed in conjunction with the patient and included with the individualized treatment plan of care.

30.13.c. For a patient projected to be involved in detoxification treatment services for six months or less, the OBMAT program must offer the patient a minimum of three counseling sessions per week for the first month and a minimum of two counseling sessions each month thereafter.

30.14. Maintenance treatment shall be discontinued within two continuous years after the treatment is begun unless, based upon the clinical judgment of the medical director or program physician and staff which shall be recorded in the client's record, the client's status indicates that the treatment should be continued for a longer period of time because discontinuance from treatment would lead to a return to illicit opiate abuse or dependence, or increased psychiatric, behavioral or medical symptomology.

§69-12-31. Administrative Withdrawal.

31.1. Administrative withdrawal is an involuntary withdrawal or administrative discharge from pharmacotherapy. The schedule of withdrawal may be brief; less than 30 days, if necessary.

31.2. OBMAT programs shall develop and implement policies and procedures for the involuntary termination from treatment that includes and describes the rights of the patient and the responsibilities and rights of the program.

31.3. On admission, the patient shall be given a copy of the administrative withdrawal policies and procedures and shall sign a statement acknowledging receipt of the same. The signed acknowledgement shall be maintained in the patient's record.

31.4. Administrative withdrawal may result from any of the following:

31.4.a. Non-payment of fees. The OBMAT program shall make every effort to consider all clinical data, including patient participation and compliance with treatment prior to initiating administrative withdrawal for non-payment. If the patient has a history of compliance and cooperation with treatment, the program shall document every effort to explore alternatives to administrative withdrawal with the patient prior to onset of withdrawal. If necessary and unavoidable, the schedule of withdrawal shall follow protocols and guidelines of approved authorities.

31.4.b. Disruptive or adverse effect conduct. Disruptive conduct or behavior considered to have an adverse effect on the program, clinical staff or patient population of such gravity as to justify the involuntary withdrawal and discharge of a patient. Such behaviors may include violence, threat of violence, dealing drugs, diversion of pharmacological agents, repeated loitering, failure to follow treatment plan objectives or noncompliance with program rules, policies and procedures resulting in an observable, negative impact on the program, staff and other patients.

31.4.c. Incarceration or other confinement. The OBMAT program is responsible for working with law enforcement and corrections personnel in order to avoid mandatory withdrawal whenever possible.

31.5. The OBMAT program shall document in the patient's individualized treatment plan of care and chart all efforts regarding referral or transfer of the patient to a suitable, alternative treatment program.

31.6. Female patients shall have a negative pregnancy screen prior to the onset of administrative withdrawal.

31.7. The program shall have in place a detailed relapse prevention plan developed by the counselor in accordance with approved national guidelines and in conjunction with the patient. The prevention plan shall be given to the patient in writing prior to the administration of the final dose of medication.

§69-12-32. Medical Withdrawal.

32.1. Medical withdrawal occurs as a voluntary and therapeutic withdrawal agreed upon by clinical staff and the patient in accordance with approved national guidelines. In some cases the withdrawal may be against the advice of clinical staff or against medical advice.

32.2. The OBMAT program shall supply a schedule of dose reduction well tolerated by the patient.

32.3. The program shall offer supportive treatment, including increased counseling sessions and referral to a self-help group or other counseling provider as appropriate.

32.4. If the patient leaves the OBMAT program abruptly against medical advice, the program may readmit the patient within 30 days without a formal reassessment procedure. However, the program must perform a physical assessment and a biopsychosocial assessment upon readmission. The program

shall document attempting to assist the patient with any issues which may have triggered his or her abrupt departure.

32.5. The OBMAT program shall make provisions for continuing care for each patient following the last dose of medication and for re-entry to maintenance treatment if relapse occurs or if the patient should reconsider withdrawal.

32.6. Female patients shall have a negative pregnancy screen prior to the onset of medically-supervised withdrawal.

32.7. The program shall have in place a detailed relapse prevention plan developed by the primary counselor in accordance with approved national guidelines and in conjunction with the patient. The prevention plan shall be given to the patient in writing prior to the administration of the final dose of medication.

§69-12-33. Laboratory Services; Drug Screens.

33.1. All patients in the OBMAT program shall undergo monthly drug testing. Random drug testing of all patients shall be conducted during the course of treatment as required in section 33.

33.2. Collection and Testing.

33.2.a. OBMAT programs shall work carefully with toxicology laboratories to ensure valid, appropriate results of toxicological screens. Workplace testing standards are not appropriate for urine testing. Testing shall be done only by laboratories with appropriate federal certification.

33.2.b. Each OBMAT program shall have the capability of obtaining medication blood levels when clinically indicated or through random or monthly drug testing of all patients.

33.2.c. Urine drug screening and other adequately tested toxicological procedures shall be used as an aid in monitoring and evaluating a patient's progress in treatment.

33.2.d. Drug screening policies and procedures shall be determined on an individualized basis for each patient, subject to the following requirements:

33.2.d.1. A patient receiving medication-assisted treatment medication maintenance services must at least one random drug screen per month during the first year of treatment and random drug screens quarterly thereafter.

33.2.d.2. A patient undergoing medically-supervised or other types of withdrawal may be required to have more frequent collection and analysis of samples.

33.2.d.3. When using urine as a screening mechanism, all patient drug testing shall be observed to minimize the chance of adulterating or substituting another individual's urine.

33.2.d.4. OBMAT programs shall develop and implement policies and procedures to minimize misidentification of urine specimens and to ensure that the tested specimens can be traced to the donor patient.

33.2.e. Drug screenings shall include toxicological analysis for drugs of abuse, including, but not limited to:

33.2.e.1. Buprenorphine, especially in ratio to Norbuprenorphine;

33.2.e.2. Opiates including oxycodone at common levels of dosing;

33.2.e.3. Methadone, medication-assisted treatment medications or any other medication used by the program as an intervention for that patient;

33.2.e.4. Benzodiazepines, including testing procedures that detect diazepam, clonazepam, alprazolam and lorazepam;

33.2.e.5. Cocaine;

33.2.e.6. Meth-amphetamine/amphetamines;

33.2.e.7. Tetrahydrocannabinol, delta-9-tetrahydrocannabinol, dronabinol or other similar substances; or

33.2.e.8. Other drugs or substances as determined by community standards, regional variation or clinical indication, such as carisoprodol or barbiturates.

33.2.f. Collection and testing shall be done in a manner that assures a method of confirmation for positive results and documents the chain of custody of the collection.

33.2.g. When necessary and appropriate, breathalyzers or other testing equipment may be used to screen for possible alcohol abuse. No individual shall receive a daily dose who has a breathalyzer result which is equal to or greater than 0.02. The individual may return to the program for dosing during the same day if the breathalyzer results reach acceptable limits.

33.2.h. Each OBMAT program shall document both the results of toxicological tests and the follow-up therapeutic action taken in the patient record.

33.2.i. Each OBMAT program shall ensure that program physician demonstrate competence in the interpretation of "false negative" and "false positive" laboratory results as they relate to physiological issues, differences among laboratories and factors that impact the absorption, metabolism and elimination of opiates.

33.2.j. The program physician shall thoroughly evaluate a positive toxicological screen for any potentially licit substance such as benzodiazepines, carisoprodol, barbiturates and amphetamines. The program shall verify with appropriate releases of information that:

33.2.j.1. The patient has been prescribed these medications by a licensed physician for a legitimate medical purpose; and

33.2.j.2. The prescribing physician is aware that the patient is enrolled in an OBMAT program.

33.2.k. If a patient refuses the release of information to contact his or her physician but can produce prescriptions or other evidence of a legitimate prescription, such as current medication bottles that are fully labeled, the interdisciplinary team shall consider the patient's individual situation and the possibility that he or she may be dismissed from the care of his or her physician if the physician discovers that the patient is in an OBMAT program. The program physician shall make the ultimate decision as to the patient's continuing care in the program and the circumstances of that care.

33.2.l. Nothing contained in this rule shall preclude any OBMAT program from administering any additional drug tests it determines are necessary.

33.3. Test Results.

33.3.a. A positive test is a test that results in the presence of any drug or substance listed in section 33.2.e. of this rule, or any other drug or substance prohibited by the OBMAT program. The presence of a drug or substance which is part of the patient's individualized treatment plan of care shall not be considered a positive test. Any refusal to participate in a random drug test shall be considered a positive drug test.

33.3.b. A positive drug test result after the first six months in an OBMAT program shall result in the following:

33.3.b.1. Upon the first positive drug test result, the OBMAT program shall provide mandatory and documented weekly counseling to the patient of no less than 30 minutes, which shall include weekly meetings with a counselor or other professional as described in section 26.5 of this rule who is licensed, certified or enrolled in the process of obtaining licensure or certification in compliance with the rules on staff at the OBMAT program or by formal referral agreement; and

33.3.b.2. Upon a second positive drug test result within six months of a previous positive drug test result, the OBMAT program shall:

33.3.b.2.A. Provide mandatory and documented weekly counseling to the patient of no less than 30 minutes, which shall include weekly meetings with a counselor or other professional as described in section 26.9 of this rule who is licensed, certified or enrolled in the process of obtaining licensure or certification in compliance with the rules on staff at the OBMAT program; and

33.3.b.2.B. Provide mandatory documented treatment to meetings with the program physician and primary counselor with the patient at OBMAT programs.

33.3.b.3. Upon a third positive drug test result within a period of six months the OBMAT program shall:

33.3.b.3.A. Provide mandatory and documented weekly counseling to the patient of no less than 30 minutes, which shall include weekly meetings with a counselor or other professional as described in section 26.9 of this rule who is licensed, certified or enrolled in the process of obtaining licensure or certification in compliance with the rules on staff at the OBMAT program; or

33.3.b.3.B. Provide mandatory and documented treatment of meetings with the program physician and primary counselor with the patient at OBMAT programs which will include, at a minimum: the need for continuing treatment; a discussion of other treatment alternatives; and the

execution of a contract with the patient advising the patient of discharge for continued positive drug tests.

33.3.b.4. Upon any subsequent positive drug test within a six month period, the patient may be immediately discharged from the OBMAT program, or, at the option of the patient, may immediately be provided the opportunity to participate in a detoxification plan, followed by immediate discharge from the OBMAT program. If a patient remains in treatment with the OBMAT programs, the primary counselor and program physician must meet with the patient and revise the individual treatment strategy or plan of care and update the coordination of care agreement.

33.3.c. Positive screens for tetrahydrocannabinol, delta-9-tetrahydrocannabinol, dronabinol or similar substances shall be carefully clinically evaluated and shall in most cases result in reduction in take-home medication privileges unless other action is considered appropriate by the medical director or program physician and primary counselor. Testing positive solely for tetrahydrocannabinol, delta-9-tetrahydrocannabinol, dronabinol or similar substances shall not serve as a basis for discharge from the program.

33.3.d. Absence of medication-assisted treatment medication prescribed by the program for the patient is evidence of possible medication diversion. Whenever there is evidence of possible medication-assisted treatment medication diversion, the patient shall be re-evaluated by the program physician at the OBMAT program and the individualized treatment strategy or plan of care shall be adjusted, if needed, accordingly.

§69-12-34. Special Populations.

34.1. Concurrent Alcohol and Polysubstance Abuse.

34.1.a. Each OBMAT program shall address abuse of alcohol and other non-opioid substances within the context of the medication-assisted therapy effort.

34.1.b. The OBMAT program shall ensure that its staff is fully trained and knowledgeable regarding current effective strategies for treating alcohol, cocaine and other drug abuse.

34.1.c. Ongoing polysubstance use is not a reason for discharge unless the patient refuses recommended, more intensive levels of care. The interdisciplinary team shall consider the patient's condition and address the situation from a clinical perspective and in accordance with guidelines and protocols from approved authorities.

34.1.d. Each OBMAT program shall have a policy regarding treatment of co-morbid disorders such as psychiatric and medical disorders. The goal of the treatment shall be to provide treatment for these disorders in as seamless a fashion as possible, maximizing patient convenience and compliance with appointments and recommendations. The program shall develop interagency agreements whenever possible to ensure smooth referral processes and interchange of information.

34.2. Behavioral Health Needs.

34.2.a. Each OBMAT program shall ensure that patients with behavioral health needs are identified through the evaluation process and referred for appropriate treatment.

34.2.b. At all phases of treatment, the OBMAT program shall monitor patients during detoxification withdrawal and recovery for indications of symptoms of behavioral illness.

34.2.c. Each OBMAT program shall establish linkages with licensed behavioral health providers in the community.

34.2.d. Each OBMAT program may provide psychotropic medication management onsite by appropriately trained medical professionals. Individualized treatment plans of care shall describe the goals of psychotropic medication management, which shall be reviewed regularly. The patient's chart and individualized treatment plan of care shall document regular contact with the prescribing physician and/or physician extender for the distinct purpose of monitoring prescribed psychotropic medications.

34.3. HIV Patients.

34.3.a. The OBMAT program shall educate all patients regarding HIV/AIDS, testing procedures, confidentiality, reporting, follow-up care, safer sex, social responsibilities and sharing of intravenous equipment.

34.b. The program shall establish linkages with HIV/AIDS treatment programs in the community.

34.4. Chronic Pain Patients.

34.4.a. Each OBMAT program shall ensure that physicians practicing at the facility are knowledgeable in the treatment and management of substance use disorder in a context of chronic pain and pain management. The program may not prohibit a patient diagnosed with chronic pain from receiving medication for either maintenance or withdrawal in a program setting.

34.4.b. Each OBMAT program shall ensure continuity of care and communication between programs or physicians regarding patients receiving treatment in both an OBMAT program and a facility or physician's office for purposes of pain management, with the patient's written permission. If a patient refuses permission for the two entities to communicate and coordinate care, the program shall document refusal and may make clinically appropriate decisions regarding take-home medication privileges and continuation in treatment.

34.5. Pregnant Patients.

34.5.a. Pregnant women seeking and needing treatment shall be enrolled in the OBMAT program and provided treatment in accordance with guidelines and protocols from approved authorities.

34.5.b. The OBMAT program shall ensure that every pregnant patient has the opportunity for prenatal care, either onsite or by referral. If the arrangement is by referral, the program shall have agreements in place, including informed consent procedures, which ensure exchange of pertinent clinical information regarding compliance with the recommended plan of medical care.

34.5.c. If not available elsewhere, the program shall offer basic instruction on OBMAternal, physical and dietary care as part of its counseling services and document the provision of the services in the clinical record.

34.5.d. With respect to pharmacotherapy for opioid addicted pregnant women in medication-assisted therapy, the program shall ensure that:

34.5.d.1. Maintenance treatment dosage levels shall be maintained at the lowest possible dosage level that is a medically appropriate therapeutic dose as determined by the medical director or program physician taking the pregnancy into account.

34.5.d.2. The initial medication-assisted treatment dose for a newly admitted pregnant patient and the subsequent induction and maintenance dosing strategy reflect the same effective dosing protocols used for all other patients;

34.5.d.3. The dose is monitored carefully, moving rapidly to supply increased or split dose if it becomes necessary; and

34.5.d.4. If a pregnant patient elects to withdraw from medication-assisted treatment, that withdrawal is not initiated by the program before 14 weeks and after 32 weeks gestation; perform regular fetal assessments as appropriate for fetal age and require that withdrawal is supervised by a physician experienced in substance use disorder medicine.

34.5.e. The OBMAT program shall ensure appropriate referral for follow-up and primary care for the mother and infant.

34.5.f. If a pregnant patient is discharged, the OBMAT program shall identify the physician to whom the patient is being discharged and this information shall be retained in the clinical record.

34.5.g. The program shall offer onsite parenting education and training to all male and female patients who are parents or shall refer interested patients to appropriate alternative services for training. Any referral shall be documented in the patient's record.

34.5.h. The program shall offer reproductive health education to all patients and appropriate referrals for contraceptive services as necessary.

34.6. Criminal Justice.

34.6.a. Each OBMAT program shall establish agreements and develop and implement procedures to coordinate with agents of the criminal justice system on behalf of patients insofar as permitted by patient confidentiality requirements.

§69-12-35. Advertisement Disclosure.

35.1. Any advertisement made by or on behalf of an OBMAT program through public media, such as a telephone directory, medical directory, newspaper or other periodical, outdoor advertising, radio or television, or through written or recorded communication, concerning the treatment of substance use disorder shall include the name of, at a minimum, one program physician responsible for the content of the advertisement.

§69-12-36. Licensure and Registration Denials, Revocations and Suspensions.

36.1. Grounds for Denial, Revocation or Suspension.

36.1.a. The secretary may deny, revoke or suspend a license or registration issued pursuant to this rule if any provisions of federal or state law or this rule are violated. The secretary may revoke a license or registration and prohibit all program physicians associated with that OBMAT program from practicing at the program location based upon the findings and results of an annual, periodic, complaint or other inspection and evaluation. The period of suspension for the license or registration of an OBMAT program shall be prescribed by the secretary, but may not exceed one year.

36.1.b. The secretary may deny, revoke or suspend an OBMAT program license or registration for one or more of the following reasons:

36.1.b.1. The secretary makes a determination that fraud or other illegal action has been committed by any owner of the OBMAT program.

36.1.b.2. The OBMAT program has violated federal, state or local law relating to licensure, registration, building, health, fire protection, safety, sanitation or zoning;

36.1.b.3. The OBMAT program engages in practices that jeopardize the health, safety, welfare or clinical treatment of a patient;

36.1.b.4. The OBMAT program has failed or refused to submit reports or make records available as requested by the secretary;

36.1.b.5. AN OBMAT program has refused to provide access to its location or records as requested by the secretary;

36.1.b.6. AN OBMAT program's medical director has knowingly and intentionally misrepresented actions taken to correct a violation;

36.1.b.7. An owner or medical director of an OBMAT program concurrently operates an unlicensed or unregistered OBMAT program;

36.1.b.8. A program physician or any owner knowingly operates, owns or manages an unlicensed or unregistered OBMAT program that is required to be licensed or registered;

36.1.b.9. The owners of an OBMAT program fail to apply for a new license or registration for the program upon a change of ownership and operate the program under the new ownership;

36.1.b.10. A program physician or any owner acquires or attempts to acquire a license or registration for an OBMAT program through misrepresentation or fraud or procures or attempts to procure a license or registration for an OBMAT program for any other person by making or causing to be made any false representation; or

36.1.b.11. The OBMAT program fails to have a medical director practicing at the program location as required by this rule.

36.2. Effect of Denial, Revocation or Suspension.

36.2.a. If a license or registration for an OBMAT program has been revoked, the secretary may stay the effective date of the revocation if the medical director, owner or owners and administrator of

the program can show that the stay is necessary to ensure appropriate referral and placement of patients.

36.2.b. If the license or registration of an OBMAT program is denied, revoked or suspended, no person, firm, association or corporation may operate the program as an OBMAT program as of the effective date of the denial, revocation or suspension. The owners of the OBMAT program are responsible for removing all signs and symbols identifying the premises as an OBMAT program within thirty days from the date of the denial, revocation or suspension.

36.2.c. If a license or registration for an OBMAT program has been denied, revoked or suspended the program must supply, at a minimum, a copy of the following information to the secretary:

36.2.c.1. A closure notice to be mailed to all active patients meeting the guidelines set forth by its respective medical board;

36.2.c.2. The date the closure letter will be mailed to all active patients;

36.2.c.3. The number of active patients to receive the closure notice;

36.2.c.4. A Class II legal advertisement that complies with the requirements of article 3, chapter 59 of the West Virginia Code regarding the program closure, including the dates the notice will appear and the name of the newspaper; and

36.2.c.5. Contact information the program has supplied to patients who may need help locating a new treating physician or program.

36.2.d. Upon the effective date of the denial, revocation or suspension the medical director of the OBMAT program shall advise the secretary and the West Virginia Board of Pharmacy of the disposition of all drugs located on the premises. The disposition is subject to the supervision and approval of the secretary and the DEA. Drugs that are purchased or held by an OBMAT program that is not licensed or registered may be deemed adulterated.

36.2.e. If the license or registration of an OBMAT program is revoked or suspended, no person named in the licensing or registering documents of the program, including persons owning or operating the OBMAT program, may apply to own, license, register or operate another OBMAT program for five years after the date of revocation or suspension, either individually or as part of a group practice, firm, association or corporation.

36.22.f. If an OBMAT program license or registration is denied or revoked, a new application for license or registration shall be considered by the secretary, if, when and after the conditions upon which denial or revocation was based have been corrected and evidence of this fact has been furnished. A new license or registration may then be granted after proper inspection has been made and the secretary makes a written finding that all provisions of this article and rules promulgated pursuant to this article have been satisfied.

§69-12-37. Penalties and Equitable Relief.

37.1. Grounds for Penalties and Injunctions.

37.1.a. Any person, partnership, association or corporation which establishes, conducts, manages or operates an OBMAT program without first obtaining a license or registration therefore or which violates any provisions of law or rule shall be assessed a civil money penalty by the secretary in accordance with this rule.

37.1.b. Each day of continuing violation after notification of the infraction shall be considered a separate violation.

37.1.c. If the OBMAT program fails to timely file reports required by section 13 of this rule, the secretary may impose a civil monetary penalty not to exceed \$1,000 per day.

37.1.d. If the OBMAT program's owner or owners, medical director and administrator knowingly and intentionally misrepresents actions taken to correct a violation, the secretary may impose a civil money penalty not to exceed \$10,000 and revoke or deny the OBMAT program's license or registration.

37.1.e. If an owner or owners or medical director of an OBMAT program concurrently operates an unlicensed or unregistered OBMAT program, the secretary may impose a civil money penalty upon the owner or owners or medical director, or both, not to exceed \$5,000 per day.

37.1.f. If the owner of an OBMAT program that requires a license or registration under this article fails to apply for a new license or registration for the program upon a change of ownership and operates the program under the new ownership, the secretary may impose a civil money penalty not to exceed \$5,000.

37.1.g. If a program physician knowingly operates, owns or manages an unlicensed or unregistered OBMAT program that is required to be licensed or registered pursuant to this article; knowingly prescribes or dispenses or causes to be prescribed or dispensed, controlled substances in an unlicensed or unregistered OBMAT program that is required to be licensed or registered; or obtains a license or registration to operate an OBMAT program through misrepresentation or fraud; procures or attempts to procure a license or registration for an OBMAT program for any other person by making or causing to be made any false representation, the secretary may assess a civil money penalty of not more than \$20,000. The penalty may be in addition to or in lieu of any other action that may be taken by the secretary or any other board, court or entity.

37.2. The secretary may deny an OBMAT program's application for licensure or registration or application for renewal license or registration; revoke or suspend a license or registration; order an admissions ban or reduction in patient census for one or more of the following reasons:

37.2.a. The secretary makes a determination that fraud or other illegal action has been committed;

37.2.b. The program has violated federal, state or local law relating to building, health, fire protection, safety, sanitation or zoning;

37.2.c. The program conducts practices that jeopardize the health, safety, welfare or clinical treatment of a patient;

37.2.d. The program has failed or refused to submit reports, comply with the documentation requirements of section 8.2.c, or make records available as requested by the secretary or his or her designee; or

37.2.e. A program has refused to provide access to its location or records as requested by the secretary, or his or her designee.

37.3. Notwithstanding the existence or pursuit of any other remedy, the secretary may, in the manner provided by law, maintain an action in the name of the state for an injunction against any person, partnership, association or corporation to restrain or prevent the establishment, conduct, management or operation of any OBMAT program or violation of any provisions of this rule without first obtaining a license or registration therefore in the manner hereinbefore provided.

37.3.a. The secretary may also seek injunctive relief if the establishment, conduct, management or operation of any OBMAT program, whether licensed, registered or not, jeopardizes the health, safety or welfare of any or all of its patients.

37.3.b. In determining whether a penalty is to be imposed and in fixing the amount of the penalty, the secretary shall consider the following factors:

37.3.b.1. The gravity of the violation, including the probability that death or serious physical or emotional harm to a patient has resulted, or could have resulted, from the OBMAT program's actions or the actions of the medical director or any treating physician employed by or associated with the program, the severity of the action or potential harm, and the extent to which the provisions of the applicable laws or rules were violated.

37.3.b.2. What actions, if any, the medical director or treating physician took to correct the violations;

37.3.b.3. Whether there were any previous violations at the OBMAT program; and

37.3.b.4. The financial benefits that the OBMAT program derived from committing or continuing to commit the violation.

37.4. Upon finding that a physician has violated the provisions of this rule, the secretary shall provide notice of the violation to the applicable licensing board.

§69-12-38. Administrative Due Process.

38.1. Before any OBMAT program license or registration is denied, suspended or revoked, written notice shall be given to the owner or owners of the program, stating the grounds of the denial, suspension, revocation or penalty and the date set for any enforcement action.

38.1.a. The notice shall be sent by certified mail to the owner(s) at the address where the OBMAT program concerned is located.

38.1.b. Within 30 days of receipt of the notice, the owner(s) may submit a request for an administrative hearing or an informal meeting to address and resolve the findings.

69 CSR 12

38.1.c. The OBMAT program and its owner or owners shall be entitled to be represented by legal counsel at the informal meeting or at the hearing at their own expense.

38.1.d. All of the pertinent provisions of W. Va. Code §§ 29A-5-1, et seq. and 69 CSR 1 shall apply to and govern any hearing authorized by this rule.

38.1.e. If an owner fails to request a hearing within the time frame specified, he or she shall be subject to the full penalty imposed.

38.1.f. The filing of a request for a hearing does not stay or supersede enforcement of the final decision or order of the secretary. The secretary may, upon good cause shown, stay such enforcement.

§69-12-39. Administrative Appeals and Judicial Review.

39.1. Any owner of an OBMAT program who disagrees with the final administration decision as a result of the hearing may, within 30 days after receiving notice of the decision, appeal the decision to the Circuit Court of Kanawha County or in the county where the petitioner resides or does business.

39.1.a. The filing of a petition for appeal does not stay or supersede enforcement of the final decision or order of the secretary. An appellant may apply to the circuit court for a stay of or to supersede the final decision or order.

39.1.b. The Circuit Court may affirm, modify or reverse the final administrative decision. The owner or owners, or the secretary may appeal the court's decision to the Supreme Court of Appeals.